Compounds specific to coronavirus S protein and uses thereof

Abstract

The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and / or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and / or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and / or prophylactically beneficial.

Description

COMPOUNDS SPECIFIC TO CORONA VIRUS S PROTEIN AND USES THEREOFREUATED APPUICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 008,545, filed on April 10, 2020, to U.S. Provisional Application No. 63 / 021,589, filed on May 7, 2020, to U.S. Provisional Application No. 63 / 046,313, filed on June 30, 2020, to U.S. Provisional Application No. 63 / 112,122, filed on November 10, 2020, to U.S. Provisional Application No. 63 / 138,886, filed on January 19, 2021, to U.S. Provisional Application No. 63 / 143,456, filed on January 29, 2021, to U.S. Provisional Application No. 63 / 147,495, filed on February 9, 2021, to U.S. Provisional Application No. 63 / 148,754, filed on February 12, 2021, to U.S. Provisional Application No. 63 / 150,413, filed on February 17, 2021, to U.S. Provisional Application No. 63 / 152,054, filed on February 22, 2021, and U.S. Provisional Application No. 63 / 163,400, filed on March 19, 2021. The entire contents of each of these applications are incorporated herein by reference.SEQUENCE FISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 6, 2021, is named 132280-00120_SL.txt and is 2,710,434 bytes in size.FIELD

[0003] This disclosure generally pertains to antibodies and antigen-binding fragments thereof, preferably human antibodies and antigen-binding fragments and / or affinity-matured variants thereof, recombinant cells engineered to express such antibodies, and compositions containing such antibodies and antigen-binding fragments thereof, wherein such antibodies and antigen-binding fragments thereof specifically bind to the S protein of coronaviruses (“CoV-S”) and therapeutic and diagnostic uses for the antibodies, antigen-binding fragments, and compositions thereof.BACKGROUND

[0004] Coronaviruses (“CoV”) are genetically classified into four major genera: the Alphacoronavirus genus (ACoV genus); the Betacoronavirus genus (BCoV genus); the Gammacoronavirus genus (CCoV genus); and Deltacoronavirus genus (DCoV genus), and while ACoV and BCoV primarily infect mammals CCoV and DCoV predominantly infect birds (Wu A. et al., Cell Host Microbe. 2020 Mar 11;27(3):325-328). Coronaviruses that infect humans were first identified in the mid-1960s, and currently, seven confirmed CoV species are known as human pathogens. Four CoV species, the HCoV-HKUl and HCoV-OC43 from the BCoV genus and the HCoV-229E and HCoV-NL63 from the ACoV genus, are endemic species in humans and cause mildrespiratory symptoms, mostly in pediatric patients (Bridle E.S., etal., BioRxiv reprint, doi: https: / / doi.org / 10.1101 / 2020.03.10.986398). The otherthree human CoV species, the SARS-CoV, the MERS-CoV, and the SARS-CoV-2 (also known as “2019-nCoV”), all of which are from the BCoV genus, have caused severe outbreaks, including the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002-2003, the Middle East Respiratory Syndrome (MERS) outbreak in 2012-2013, and the current (2019-) pandemic of the coronavirus disease of 2019 (“COVID-19”).

[0005] The genome of coronaviruses, whose size ranges between approximately 26,000 and 32,000 bases, includes a variable number (from 6 to 11) of open reading frames (“ORFs”) (Wu A. et al, Cell Host Microbe. 2020 Mar 11 ;27(3): 325-328) . The first ORF encodes 16 non-structural proteins (“nsps”), and the remaining ORFs encode accessory proteins and structural proteins. The four major structural proteins are the spike surface glycoprotein (“S protein” or “S” or “spike protein”), small envelope protein (“E protein” or “E”), matrix protein (“M protein” or “M”), and nucleocapsid protein (“N protein”, or “N”).

[0006] The S protein, which plays an essential role in binding to receptors on the host cell and determines host tropism (Zhu Z. et al, Infect Genet Evol. 2018 Jul;61 : 183-184), forms homotrimers protruding from the viral surface (Li F. Annu Rev Virol. 2016 Sep 29;3(1):237-261). The S protein is processed into two non-covalently associated subunits, SI and S2, and each monomer in the trimeric S assembly is a heterodimer of S 1 and S2 subunits. Cryo-EM studies have revealed that the S 1 subunit is comprised of four domains: an N-terminal domain (NTD), a C-terminal domain (CTD), and two subdomains (Walls A. C. et al, Nature 531, 114-117 (2016).; Tortorici M. A. and Veesler D.,Adv Virus Res. 2019;105:93-116; Wrapp D. etal, Science 367, 1260-1263 (2020)). The CTD functions as the receptor-binding domain (RBD) for both SARS-CoV and SARS-CoV-2 (Li F. J Virol. 2015 Feb;89(4): 1954-64). The S2 subunit contains the fusion peptide, heptad repeat 1 and 2, and a transmembrane domain, all of which are required to mediate fusion of the viral and host cell membranes.

[0007] SARS-CoV and SARS-CoV-2 bind to and use angiotensin-converting enzyme 2 (ACE2) of a host cell as a receptor to enter the host cells (Ge X.Y. et al, Nature. 2013 Nov 28;503(7477):535-8; Hoffmann M. et al, Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4). The motif within the RBD that particularly binds to RCE2 is often referred to as the “ACE2 -binding motif’. SARS-CoV can also use CD209L (also known as L-SIGN) as an alternative receptor (Jeffers S. A. et al, Proc Natl Acad Sci U S A. 2004 Nov 2;101(44): 15748-53). In contrast, MERS-CoV binds dipeptidyl peptidase 4 (“DPP4”, also known as CD26) of the host cell via a different RBD of the S protein.

[0008] Cell entry of coronaviruses often depends also on priming of the S protein by host cell proteases. Recently, SARS-CoV-2 was found to use the serine protease TMPRSS2 for S protein priming and ACE2 for entry (Wu A. etal, Cell Host Microbe. 2020 Mar 11;27(3):325-328;Hoffmann M. etal, Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4).

[0009] The genome of SARS-CoV-2 is about 29.8 kb nucleotides and encodes 15 nsps, four structural proteins (S, E, M, and N) and eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and orfl4) (Wu A. et al, Cell Host Microbe. 2020 Mar 11;27(3):325-328). While SARS-CoV-2 is genetically close to a SARS-like bat CoV and also to SARS-CoV, a number of sequence differences have been identified. When SARS-CoV-2 is compared to SARS-CoV or SARS-like bat CoV, 380 amino acid differences or substitutions were found, 27 of which are in the S protein, including 6 substitutions in the RBD at amino acid region 357-528 (but not in the receptor-binding motifs that directly interact with ACE2) and 6 substitutions in the underpinning subdomain (SD) at amino acid region 569-655.

[0010] One of the few drugs approved by the U.S. Food and Drug Administration (“FDA”) for use in treating COVID-19 is the viral replication inhibitor remdesivir. Clinical trials demonstrated that remdesivir shortens the time to recovery in hospitalized patients, but more effective therapy is in great need. Convalescent plasma received the emergency use authorization status by the FDA. Other treatments given to COVID-19 patients include anti-inflammatories such as corticosteroids and other treatments for managing symptoms such as supplemental oxygen and mechanical ventilatory support. Several drugs, particularly those that have been approved for preventing or treating other infectious disease, are currently being tested in the clinic, which includes e.g., lopinavir-ritonavir (HIV protease inhibitor), ABX464 (viral RNA splicer), favilavir (RNA-dependent RNA polymerase inhibitor used for influenza virus infection), niclosamide and ivermectin (antihelmintic), and BCG vaccine (vaccine for tuberculosis). Also, other ongoing clinical trials reportedly are using IF-6 receptor antagonist antibodies, an anti-GM-CSF or anti-GM-CSF receptor antibody, an anti-TNF antibody, an anti-IF- lbeta antibody, or an anti-complement component 5 antibody, in an effort to inhibit inflammation and thereby potentially inhibit cytokine storm and sepsis which can manifest in some SARS-CoV-2- infected patients and may cause death.SUMMARY

[0011] In one aspect, the present disclosure relates to a compound which binds to coronavirus (CoV) or the spike protein (S protein) of a CoV (“CoV-S”). In some embodiments, the compound may be an isolated antibody or antigen-binding antibody fragment which binds to a CoV-S. In some embodiments, the antibody or antigen-binding antibody fragment may comprise a heavy chain variable region (VH), or fragments thereof, and / or a light chain variable region (VL), or fragments thereof. In certain embodiments, the VH or fragment thereof may comprise a complementarity determining region 1 (CDR1), a complementarity-determining region 2 (CDR2), and a complementarity-determining region 3 (CDR3), which may also be referred to as VH CDR1, VH CDR2, and VH CDR3, respectively. In certain embodiments, the VL or fragment thereof may comprise a CDR1, a CDR2, and a CDR3, which may also be referred to as VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the antibody, or antigen-binding antibody fragmentthereof, may comprise a heavy chain CDR1, a heavy chain CDR2. a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3.

[0012] In some embodiments, the antibody or antigen-binding antibody fragment may comprise an antibody or antigen-binding antibody fragment thereof, or an affinity-matured variant of an anti-CoV- S antibody or antigen-binding antibody fragment thereof; selected from the group consisting of ADI- 55688, ADI-55689, ADI-55690, ADI-55691, ADI-55692, ADI-55693, ADI-55694, ADI-55695, ADI- 55696, ADI-55697, ADI-55698, ADI-55699, ADI-55700, ADI-55701, ADI-55702, ADI-55703, ADI- 55704, ADI-55705, ADI-55706, ADI-55707, ADI-55708, ADI-55709, ADI-55710, ADI-55711, ADI- 55712, ADI-55713, ADI-55714, ADI-55715, ADI-55716, ADI-55717, ADI-55718, ADI-55719, ADI- 55721, ADI-55722, ADI-55723, ADI-55724, ADI-55725, ADI-55726, ADI-55727, ADI-55728, ADI- 55729, ADI-55730, ADI-55731, ADI-55732, ADI-55733, ADI-55734, ADI-55735, ADI-55736, ADI- 55737, ADI-55738, ADI-55739, ADI-55740, ADI-55741, ADI-55742, ADI-55743, ADI-55744, ADI- 55745, ADI-55746, ADI-55747, ADI-55748, ADI-55749, ADI-55750, ADI-55751, ADI-55752, ADI- 55753, ADI-55754, ADI-55755, ADI-55756, ADI-55757, ADI-55758, ADI-55720, ADI-55760, ADI- 55761, ADI-55762, ADI-55763, ADI-55765, ADI-55766, ADI-55767, ADI-55769, ADI-55770, ADI- 55771, ADI-55775, ADI-55776, ADI-55777, ADI-55950, ADI-55951, ADI-55952, ADI-55953, ADI- 55954, ADI-55955, ADI-55956, ADI-55957, ADI-55958, ADI-55959, ADI-55960, ADI-55961, ADI- 55962, ADI-55963, ADI-55964, ADI-55965, ADI-55966, ADI-55967, ADI-55968, ADI-55969, ADI- 55970, ADI-55972, ADI-55973, ADI-55974, ADI-55975, ADI-55976, ADI-55977, ADI-55978, ADI- 55979, ADI-55980, ADI-55981 ADI-55982, ADI-55984, ADI-55986, ADI-55988, ADI-55989, ADI- 55990, ADI-55992, ADI-55993, ADI-55994, ADI-55995, ADI-55996, ADI-55997, ADI-55998, ADI- 55999, ADI-56000, ADI-56001, ADI-56002, ADI-56003, ADI-56004, ADI-56005 ADI-56006, ADI- 56007, ADI-56008, ADI-56009, ADI-56010, ADI-56011, ADI-56012, ADI-56013, ADI-56014, ADI- 56015, ADI-56016, ADI-56017, ADI-56018, ADI-56019, ADI-56020, ADI-56021, ADI-56022, ADI- 56023, ADI-56024, ADI-56025, ADI-56026, ADI-56027, ADI-56028, ADI-56029, ADI-56030, ADI- 56031, ADI-56032, ADI-56033, ADI-56034, ADI-56035, ADI-56037, ADI-56038, ADI-56039, ADI- 56040, ADI-56041, ADI-56042, ADI-56043, ADI-56044, ADI-56045, ADI-56046, ADI-56047, ADI- 56048, ADI-56049, ADI-56050, ADI-56051, ADI-56052, ADI-56053, ADI-56054, ADI-56055, ADI- 56056, ADI-56057, ADI-56058, ADI-56059, ADI-56061, ADI-56062, ADI-56063, ADI-56064, ADI- 56065, ADI-56066, ADI-56067, ADI-56068, ADI-56069, ADI-56070, ADI-56071, ADI-56072, ADI- 56073, ADI-56074, ADI-56075 ADI-56076, ADI-56078, ADI-56079, ADI-56080, ADI-56081, ADI- 56082, ADI-56083, ADI-56084, ADI-56443, ADI-56479, ADI-58120, ADI-58121, ADI-58122, ADI- 58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI- 58131, ADI-58130_LCN30cQ, and ADI-59988, optionally wherein the CoV-S is SARS-CoV-S orSARS-CoV-2-S.

[0013] In particular embodiments, the antibody or antigen-binding antibody fragment may comprise ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, or ADI-56046, or an antigen-binding antibody fragment thereof; or an affinity -matured variant of an anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, and ADI-56046.

[0014] In particular embodiments, the antibody or antigen-binding antibody fragment may comprise ADI-55689, ADI-55688, or ADI-56046, or an antigen-binding antibody fragment thereof, or an affinity-matured variant of an anti-CoV-S antibody ADI-55689, ADI-55688, or ADI-56046, or an antigen-binding antibody fragment thereof.

[0015] In further particular embodiments, the affinity-matured variant may be ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI- 58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI- 58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, or ADI-59988.

[0016] In some embodiments, the antibody, or antigen-binding antibody fragment thereof, may comprise a VH and / or VL. In certain embodiments, the VH may comprise a CDR3 having an amino acid sequence identical to the VH CDR3 of any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36, and optionally, the VL CDR3 may comprise a CDR3 having an amino acid sequence identical to the VL CDR3 of the same anti-CoV-S antibody that the VH CDR3 is derived from, and the anti-CoV-S antibody may be selected from any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36. Here, the CoV-S may be the spike protein (“S protein”) of Severe Acute Respiratory Syndrome (SARS) coronavirus (“SARS-CoV”), which may be referred to as “SARS-CoV-S”, or the S protein of SARS-CoV-2 (also known as “n2019-nCoV”), which may be referred to as “SARS-CoV-2-S”. Optionally, the CoV-S may comprise a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, comprising, or consisting of the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB:6VSB B) or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, comprising, or consisting of SEQ ID NO: 5 (SARS-CoV-2-S, 1273 amino acids, GenBank: QHD43416.1).

[0017] In some preferred embodiments, the VH comprises a CDR3 having an amino acid sequence identical to the VH CDR3 of an anti-CoV-S antibody selected from the group consisting of ADI- 55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI- 56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI- 58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI- 58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988. Optionally, theVL comprises a VL CDR3 having an amino acid sequence identical to the CDR3 of the same anti- CoV-S antibody from which the VH CDR3 is derived.

[0018] Further optionally, the isolated antibody or antigen-binding antibody fragment may (a) cross- react with SARS-CoV-S and SARS-CoV-2-S; and (b) may comprise the same VH CDR3 polypeptide sequence as ADI-55708, ADI-55709, or ADI-55719, which is ARGSLSREYDFLTAPQNGPWFDS (SEQ ID NO: 2108, 2208, or 3208); and optionally (c) may further comprise the same VH CDR1 polypeptide sequence as ADI-55708, ADI-55709, or ADI-55719VH.

[0019] In some embodiments, the antibody or antigen-binding antibody fragment, optionally an affinity-matured variant of any of the anti-CoV-S antibodies disclosed herein, may comprise at least 1, 2, 3, 4, 5 or all 6 complementarity-determining regions (CDRs) of any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36, optionally wherein the CoV-S is SARS-CoV-S or SARS-CoV-2-S. Optionally, the CoV-S may comprise the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB: 6VSB_B) or SEQ ID NO: 5 (SARS-CoV-2-S, 1273 amino acids, GenBank: QHD43416.1).

[0020] In some preferred embodiments, the antibody or antigen-binding antibody fragment comprises at least 1, 2, 3, 4, 5 or all 6 complementarity -determining regions (CDRs) of an anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0021] In some embodiments, the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant of any of the anti-CoV-S antibodies disclosed herein, may comprise: (a) a VH CDR1 polypeptide; (b) a VH CDR2 polypeptide; (c) a VH CDR3 polypeptide; (d) a VL CDR1 polypeptide; (e) a VL CDR2 polypeptide; and (f) a VL CDR3 polypeptide. The amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36. Optionally, the CoV-S may be SARS-CoV-S or of “SARS-CoV-2-S”. Further optionally, the CoV-S may comprise the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB: 6VSB_B) or SEQ ID NO: 5 (SARS-CoV-2-S, 1273 amino acids, GenBank: QHD43416.1).

[0022] In particular embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3,respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI- 55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI- 57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI- 58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI- 58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0023] In further particular embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0024] In further preferred embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI- 58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI- 58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0025] In certain embodiments, the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant of any of the anti-CoV-S antibodies disclosed herein, which specifically binds to CoV-S, may comprise: (a) a VH comprising a VH CDR1, VH CDR2, and VH CDR3; and (b) a VL comprising a VL CDR1, VL CDR2, and VL CDR3.

[0026] In some exemplary embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of:(1) SEQ ID NOS: 104, 106, 108, 114, 116, and 118, respectively;(2) SEQ ID NOS: 204, 206, 208, 214, 216, and 218, respectively;(3) SEQ ID NOS: 304, 306, 308, 314, 316, and 318, respectively;(4) SEQ ID NOS: 404, 406, 408, 414, 416, and 418, respectively;(5) SEQ ID NOS: 504, 506, 508, 514, 516, and 518, respectively;(6) SEQ ID NOS: 604, 606, 608, 614, 616, and 618, respectively;(7) SEQ ID NOS: 704, 706, 708, 714, 716, and 718, respectively;(8) SEQ ID NOS: 804, 806, 808, 814, 816, and 818, respectively;(9) SEQ ID NOS: 904, 906, 908, 914, 916, and 918, respectively;(10) SEQ ID NOS: 1004, 1006, 1008, 1014, 1016, and 1018, respectively;(11) SEQ ID NOS: 1104, 1106, 1108, 1114, 1116, and 1118, respectively;(12) SEQ ID NOS: 1204, 1206, 1208, 1214, 1216, and 1218, respectively;(13) SEQ ID NOS: 1304, 1306, 1308, 1314, 1316, and 1318, respectively;(14) SEQ ID NOS: 1404, 1406, 1408, 1414, 1416, and 1418, respectively;(15) SEQ ID NOS: 1504, 1506, 1508, 1514, 1516, and 1518, respectively;(16) SEQ ID NOS: 1604, 1606, 1608, 1614, 1616, and 1618, respectively;(17) SEQ ID NOS: 1704, 1706, 1708, 1714, 1716, and 1718, respectively;(18) SEQ ID NOS: 1804, 1806, 1808, 1814, 1816, and 1818, respectively;(19) SEQ ID NOS: 1904, 1906, 1908, 1914, 1916, and 1918, respectively;(20) SEQ ID NOS: 2004, 2006, 2008, 2014, 2016, and 2018, respectively;(21) SEQ ID NOS: 2104, 2106, 2108, 2114, 2116, and 2118, respectively;(22) SEQ ID NOS: 2204, 2206, 2208, 2214, 2216, and 2218, respectively;(23) SEQ ID NOS: 2304, 2306, 2308, 2314, 2316, and 2318, respectively;(24) SEQ ID NOS: 2404, 2406, 2408, 2414, 2416, and 2418, respectively;(25) SEQ ID NOS: 2504, 2506, 2508, 2514, 2516, and 2518, respectively;(26) SEQ ID NOS: 2604, 2606, 2608, 2614, 2616, and 2618, respectively;(27) SEQ ID NOS: 2704, 2706, 2708, 2714, 2716, and 2718, respectively;(28) SEQ ID NOS: 2804, 2806, 2808, 2814, 2816, and 2818, respectively;(29) SEQ ID NOS: 2904, 2906, 2908, 2914, 2916, and 2918, respectively;(30) SEQ ID NOS: 3004, 3006, 3008, 3014, 3016, and 3018, respectively;(31) SEQ ID NOS: 3104, 3106, 3108, 3114, 3116, and 3118, respectively;(32) SEQ ID NOS: 3204, 3206, 3208, 3214, 3216, and 3218, respectively;(33) SEQ ID NOS: 3304, 3306, 3308, 3314, 3316, and 3318, respectively;(34) SEQ ID NOS: 3404, 3406, 3408, 3414, 3416, and 3418, respectively;(35) SEQ ID NOS: 3504, 3506, 3508, 3514, 3516, and 3518, respectively;(36) SEQ ID NOS: 3604, 3606, 3608, 3614, 3616, and 3618, respectively;(37) SEQ ID NOS: 3704, 3706, 3708, 3714, 3716, and 3718, respectively;(38) SEQ ID NOS: 3804, 3806, 3808, 3814, 3816, and 3818, respectively;(39) SEQ ID NOS: 3904, 3906, 3908, 3914, 3916, and 3918, respectively;(40) SEQ ID NOS: 4004, 4006, 4008, 4014, 4016, and 4018, respectively;(41) SEQ ID NOS: 4104, 4106, 4108, 4114, 4116, and 4118, respectively;(42) SEQ ID NOS: 4204, 4206, 4208, 4214, 4216, and 4218, respectively;(43) SEQ ID NOS: 4304, 4306, 4308, 4314, 4316, and 4318, respectively;(44) SEQ ID NOS: 4404, 4406, 4408, 4414, 4416, and 4418, respectively;(45) SEQ ID NOS: 4504, 4506, 4508, 4514, 4516, and 4518, respectively;(46) SEQ ID NOS: 4604, 4606, 4608, 4614, 4616, and 4618, respectively;(47) SEQ ID NOS: 4704, 4706, 4708, 4714, 4716, and 4718, respectively;(48) SEQ ID NOS: 4804, 4806, 4808, 4814, 4816, and 4818, respectively;(49) SEQ ID NOS: 4904, 4906, 4908, 4914, 4916, and 4918, respectively;(50) SEQ ID NOS: 5004, 5006, 5008, 5014, 5016, and 5018, respectively;(51) SEQ ID NOS: 5104, 5106, 5108, 5114, 5116, and 5118, respectively;(52) SEQ ID NOS: 5204, 5206, 5208, 5214, 5216, and 5218, respectively;(53) SEQ ID NOS: 5304, 5306, 5308, 5314, 5316, and 5318, respectively;(54) SEQ ID NOS: 5404, 5406, 5408, 5414, 5416, and 5418, respectively;(55) SEQ ID NOS: 5504, 5506, 5508, 5514, 5516, and 5518, respectively;(56) SEQ ID NOS: 5604, 5606, 5608, 5614, 5616, and 5618, respectively;(57) SEQ ID NOS: 5704, 5706, 5708, 5714, 5716, and 5718, respectively;(58) SEQ ID NOS: 5804, 5806, 5808, 5814, 5816, and 5818, respectively;(59) SEQ ID NOS: 5904, 5906, 5908, 5914, 5916, and 5918, respectively;(60) SEQ ID NOS: 6004, 6006, 6008, 6014, 6016, and 6018, respectively;(61) SEQ ID NOS: 6124, 6106, 6108, 6114, 6161, and 6118, respectively;(62) SEQ ID NOS: 6204, 6206, 6208, 6214, 6216, and 6218, respectively;(63) SEQ ID NOS: 6304, 6306, 6308, 6314, 6316, and 6318, respectively;(64) SEQ ID NOS: 6404, 6406, 6408, 6414, 6416, and 6418, respectively;(65) SEQ ID NOS: 6504, 6506, 6508, 6514, 6516, and 6518, respectively;(66) SEQ ID NOS: 6604, 6606, 6608, 6614, 6616, and 6618, respectively;(67) SEQ ID NOS: 6704, 6706, 6708, 6714, 6716, and 6718, respectively;(68) SEQ ID NOS: 6804, 6806, 6808, 6814, 6816, and 6818, respectively;(69) SEQ ID NOS: 6904, 6906, 6908, 6914, 6916, and 6918, respectively;(70) SEQ ID NOS: 7004, 7006, 7008, 7014, 7016, and 7018, respectively;(71) SEQ ID NOS: 7104, 7106, 7108, 7114, 7116, and 7118, respectively.(72) SEQ ID NOS: 7204, 7206, 7208, 7214, 7216, and 7218, respectively;(73) SEQ ID NOS: 7304, 7306, 7308, 7314, 7316, and 7318, respectively;(74) SEQ ID NOS: 7404, 7406, 7408, 7414, 7416, and 7418, respectively;(75) SEQ ID NOS: 7504, 7506, 7508, 7514, 7516, and 7518, respectively;(76) SEQ ID NOS: 7604, 7606, 7608, 7614, 7616, and 7618, respectively;(77) SEQ ID NOS: 7704, 7706, 7708, 7714, 7716, and 7718, respectively;(78) SEQ ID NOS: 7804, 7806, 7808, 7814, 7816, and 7818, respectively;(79) SEQ ID NOS: 7904, 7906, 7908, 7914, 7916, and 7918, respectively;(80) SEQ ID NOS: 8004, 8006, 8008, 8014, 8016, and 8018, respectively;(81) SEQ ID NOS: 8104, 8106, 8108, 8114, 8116, and 8118, respectively;(82) SEQ ID NOS: 8204, 8206, 8208, 8214, 8216, and 8218, respectively;(83) SEQ ID NOS: 8304, 8306, 8308, 8314, 8316, and 8318, respectively;(84) SEQ ID NOS: 8404, 8406, 8408, 8414, 8416, and 8418, respectively;(85) SEQ ID NOS: 8504, 8506, 8508, 8514, 8516, and 8518, respectively;(86) SEQ ID NOS: 8604, 8606, 8608, 8614, 8616, and 8618, respectively;(87) SEQ ID NOS: 8704, 8706, 8708, 8714, 8716, and 8718, respectively;(88) SEQ ID NOS: 8804, 8806, 8808, 8814, 8816, and 8818, respectively;(89) SEQ ID NOS: 8904, 8906, 8908, 8914, 8916, and 8918, respectively;(90) SEQ ID NOS: 9004, 9006, 9008, 9014, 9016, and 9018, respectively; (101) SEQ ID NOS: 10104, 10106, 10108, 10114, 10116, and 10118, respectively; (102) SEQ ID NOS: 10204, 10206, 10208, 10214, 10216, and 10218, respectively;(103) SEQ ID NOS: 10304, 10306, 10308, 10314, 10316, and 10318, respectively;(104) SEQ ID NOS: 10404, 10406, 10408, 10414, 10416, and 10418, respectively;(105) SEQ ID NOS: 10504, 10506, 10508, 10514, 10516, and 10518, respectively;(106) SEQ ID NOS: 10604, 10606, 10608, 10614, 10616, and 10618, respectively;(107) SEQ ID NOS: 10704, 10706, 10708, 10714, 10716, and 10718, respectively;(108) SEQ ID NOS: 10804, 10806, 10808, 10814, 10816, and 10818, respectively;(109) SEQ ID NOS: 10904, 10906, 10908, 10914, 10916, and 10918, respectively;(110) SEQ ID NOS: 11004, 11006, 11008, 11014, 11016, and 11018, respectively; (111) SEQ ID NOS: 11104, 11106, 11108, 11114, 11116, and 11118, respectively; (112) SEQ ID NOS: 11204, 11206, 11208, 11214, 11216, and 11218, respectively;(113) SEQ ID NOS: 11304, 11306, 11308, 11314, 11316, and 11318, respectively;(114) SEQ ID NOS: 11404, 11406, 11408, 11414, 11416, and 11418, respectively;(115) SEQ ID NOS: 11504, 11506, 11508, 11514, 11516, and 11518, respectively;(116) SEQ ID NOS: 11604, 11606, 11608, 11614, 11616, and 11618, respectively;(117) SEQ ID NOS: 11704, 11706, 11708, 11714, 11716, and 11718, respectively;(118) SEQ ID NOS: 11804, 11806, 11808, 11814, 11816, and 11818, respectively;(119) SEQ ID NOS: 11904, 11906, 11908, 11914, 11916, and 11918, respectively;(120) SEQ ID NOS: 12004, 12006, 12008, 12014, 12016, and 12018, respectively; (121) SEQ ID NOS: 12104, 12106, 12108, 12114, 12116, and 12118, respectively; (122) SEQ ID NOS: 12204, 12206, 12208, 12214, 12216, and 12218, respectively;(123) SEQ ID NOS: 12304, 12306, 12308, 12314, 12316, and 12318, respectively;(124) SEQ ID NOS: 12404, 12406, 12408, 12414, 12416, and 12418, respectively;(125) SEQ ID NOS: 12504, 12506, 12508, 12514, 12516, and 12518, respectively;(126) SEQ ID NOS: 12604, 12606, 12608, 12614, 12616, and 12618, respectively;(127) SEQ ID NOS: 12704, 12706, 12708, 12714, 12716, and 12718, respectively;(128) SEQ ID NOS: 12804, 12806, 12808, 12814, 12816, and 12818, respectively;(129) SEQ ID NOS: 12904, 12906, 12908, 12914, 12916, and 12918, respectively;(130) SEQ ID NOS: 13004, 13006, 13008, 13014, 13016, and 13018, respectively;(131) SEQ ID NOS: 13104, 13106, 13108, 13114, 13116, and 13118, respectively;(132) SEQ ID NOS: 13204, 13206, 13208, 13214, 13216, and 13218, respectively;(133) SEQ ID NOS: 13304, 13306, 13308, 13314, 13316, and 13318, respectively;(134) SEQ ID NOS: 13404, 13406, 13408, 13414, 13416, and 13418, respectively;(135) SEQ ID NOS: 13504, 13506, 13508, 13514, 13516, and 13518, respectively;(136) SEQ ID NOS: 13604, 13606, 13608, 13614, 13616, and 13618, respectively;(137) SEQ ID NOS: 13704, 13706, 13708, 13714, 13716, and 13718, respectively;(138) SEQ ID NOS: 13804, 13806, 13808, 13814, 13816, and 13818, respectively;(139) SEQ ID NOS: 13904, 13906, 13908, 13914, 13916, and 13918, respectively;(140) SEQ ID NOS: 14004, 14006, 14008, 14014, 14016, and 14018, respectively;(141) SEQ ID NOS: 14104, 14106, 14108, 14114, 14116, and 14118, respectively;(142) SEQ ID NOS: 14204, 14206, 14208, 14214, 14216, and 14218, respectively;(143) SEQ ID NOS: 14304, 14306, 14308, 14314, 14316, and 14318, respectively;(144) SEQ ID NOS: 14404, 14406, 14408, 14414, 14416, and 14418, respectively;(145) SEQ ID NOS: 14504, 14506, 14508, 14514, 14516, and 14518, respectively;(146) SEQ ID NOS: 14604, 14606, 14608, 14614, 14616, and 14618, respectively;(147) SEQ ID NOS: 14704, 14706, 14708, 14714, 14716, and 14718, respectively;(148) SEQ ID NOS: 14804, 14806, 14808, 14814, 14816, and 14818, respectively;(149) SEQ ID NOS: 14904, 14906, 14908, 14914, 14916, and 14918, respectively;(150) SEQ ID NOS: 15004, 15006, 15008, 15014, 15016, and 15018, respectively;(151) SEQ ID NOS: 15104, 15106, 15108, 15114, 15116, and 15118, respectively;(152) SEQ ID NOS: 15204, 15206, 15208, 15214, 15216, and 15218, respectively;(153) SEQ ID NOS: 15304, 15306, 15308, 15314, 15316, and 15318, respectively;(154) SEQ ID NOS: 15404, 15406, 15408, 15414, 15416, and 15418, respectively;(155) SEQ ID NOS: 15504, 15506, 15508, 15514, 15516, and 15518, respectively;(156) SEQ ID NOS: 15604, 15606, 15608, 15614, 15616, and 15618, respectively;(157) SEQ ID NOS: 15704, 15706, 15708, 15714, 15716, and 15718, respectively;(158) SEQ ID NOS: 15804, 15806, 15808, 15814, 15816, and 15818, respectively;(159) SEQ ID NOS: 15904, 15906, 15908, 15914, 15916, and 15918, respectively;(160) SEQ ID NOS: 16004, 16006, 16008, 16014, 16016, and 16018, respectively; (161) SEQ ID NOS: 16104, 16106, 16108, 16114, 16116, and 16118, respectively; (162) SEQ ID NOS: 16204, 16206, 16208, 16214, 16216, and 16218, respectively;(163) SEQ ID NOS: 16304, 16306, 16308, 16314, 16316, and 16318, respectively;(164) SEQ ID NOS: 16404, 16406, 16408, 16414, 16416, and 16418, respectively;(165) SEQ ID NOS: 16504, 16506, 16508, 16514, 16516, and 16518, respectively;(166) SEQ ID NOS: 16604, 16606, 16608, 16614, 16616, and 16618, respectively;(167) SEQ ID NOS: 16704, 16706, 16708, 16714, 16716, and 16718, respectively;(168) SEQ ID NOS: 16804, 16806, 16808, 16814, 16816, and 16818, respectively;(169) SEQ ID NOS: 16904, 16906, 16908, 16914, 16916, and 16918, respectively;(170) SEQ ID NOS: 17004, 17006, 17008, 17014, 17016, and 17018, respectively;(171) SEQ ID NOS: 17104, 17106, 17108, 17114, 17116, and 17118, respectively;(172) SEQ ID NOS: 17204, 17206, 17208, 17214, 17216, and 17218, respectively;(173) SEQ ID NOS: 17304, 17306, 17308, 17314, 17316, and 17318, respectively;(174) SEQ ID NOS: 17404, 17406, 17408, 17414, 17416, and 17418, respectively;(175) SEQ ID NOS: 17504, 17506, 17508, 17514, 17516, and 17518, respectively;(176) SEQ ID NOS: 17604, 17606, 17608, 17614, 17616, and 17618, respectively;(177) SEQ ID NOS: 17704, 17706, 17708, 17714, 17716, and 17718, respectively;(178) SEQ ID NOS: 17804, 17806, 17808, 17814, 17816, and 17818, respectively;(179) SEQ ID NOS: 17904, 17906, 17908, 17914, 17916, and 17918, respectively;(180) SEQ ID NOS: 18004, 18006, 18008, 18014, 18016, and 18018, respectively; (181) SEQ ID NOS: 18104, 18106, 18108, 18114, 18116, and 18118, respectively; (182) SEQ ID NOS: 18204, 18206, 18208, 18214, 18216, and 18218, respectively;(183) SEQ ID NOS: 18304, 18306, 18308, 18314, 18316, and 18318, respectively;(184) SEQ ID NOS: 18404, 18406, 18408, 18414, 18416, and 18418, respectively;(185) SEQ ID NOS: 18504, 18506, 18508, 18514, 18516, and 18518, respectively;(186) SEQ ID NOS: 18604, 18606, 18608, 18614, 18616, and 18618, respectively;(187) SEQ ID NOS: 18704, 18706, 18708, 18714, 18716, and 18718, respectively;(188) SEQ ID NOS: 18804, 18806, 18808, 18814, 18816, and 18818, respectively;(189) SEQ ID NOS: 18904, 18906, 18908, 18914, 18916, and 18918, respectively;(190) SEQ ID NOS: 19004, 19006, 19008, 19014, 19016, and 19018, respectively;(191) SEQ ID NOS: 19104, 19106, 19108, 19114, 19116, and 19118, respectively;(192) SEQ ID NOS: 19204, 19206, 19208, 19214, 19216, and 19218, respectively;(193) SEQ ID NOS: 19304, 19306, 19308, 19314, 19316, and 19318, respectively;(194) SEQ ID NOS: 19404, 19406, 19408, 19414, 19416, and 19418, respectively;(195) SEQ ID NOS: 19504, 19506, 19508, 19514, 19516, and 19518, respectively;(196) SEQ ID NOS: 19604, 19606, 19608, 19614, 19616, and 19618, respectively;(197) SEQ ID NOS: 19704, 19706, 19708, 19714, 19716, and 19718, respectively;(198) SEQ ID NOS: 19804, 19806, 19808, 19814, 19816, and 19818, respectively;(199) SEQ ID NOS: 19904, 19906, 19908, 19914, 19916, and 19918, respectively;(200) SEQ ID NOS: 20004, 20006, 20008, 20014, 20016, and 20018, respectively;(201) SEQ ID NOS: 20104, 20106, 20108, 20114, 20116, and 20118, respectively;(202) SEQ ID NOS: 20204, 20206, 20208, 20214, 20216, and 20218, respectively;(203) SEQ ID NOS: 20304, 20306, 20308, 20314, 20316, and 20318, respectively;(204) SEQ ID NOS: 20404, 20406, 20408, 20414, 20416, and 20418, respectively;(205) SEQ ID NOS: 20504, 20506, 20508, 20514, 20516, and 20518, respectively;(206) SEQ ID NOS: 20604, 20606, 20608, 20614, 20616, and 20618, respectively;(207) SEQ ID NOS: 20704, 20706, 20708, 20714, 20716, and 20718, respectively;(208) SEQ ID NOS: 20804, 20806, 20808, 20814, 20816, and 20818, respectively;(209) SEQ ID NOS: 20904, 20906, 20908, 20914, 20916, and 20918, respectively;(210) SEQ ID NOS: 21004, 21006, 21008, 21014, 21016, and 21018, respectively;(211) SEQ ID NOS: 21104, 21106, 21108, 21114, 21116, and 21118, respectively;(212) SEQ ID NOS: 21204, 21206, 21208, 21214, 21216, and 21218, respectively;(213) SEQ ID NOS: 21304, 21306, 21308, 21314, 21316, and 21318, respectively;(214) SEQ ID NOS: 21404, 21406, 21408, 21414, 21416, and 21418, respectively;(215) SEQ ID NOS: 21504, 21506, 21508, 21514, 21516, and 21518, respectively;(216) SEQ ID NOS: 21604, 21606, 21608, 21614, 21616, and 21618, respectively;(217) SEQ ID NOS: 21704, 21706, 21708, 21714, 21716, and 21718, respectively;(218) SEQ ID NOS: 21804, 21806, 21808, 21814, 21816, and 21818, respectively;(219) SEQ ID NOS: 21904, 21906, 21908, 21914, 21916, and 21918, respectively;(220) SEQ ID NOS: 22004, 22006, 22008, 22014, 22016, and 22018, respectively;(221) SEQ ID NOS: 22104, 22106, 22108, 22114, 22116, and 22118, respectively;(222) SEQ ID NOS: 22204, 22206, 22208, 22214, 22216, and 22218, respectively;(223) SEQ ID NOS: 22304, 22306, 22308, 22314, 22316, and 22318, respectively;(224) SEQ ID NOS: 22404, 22406, 22408, 22414, 22416, and 22418, respectively;(225) SEQ ID NOS: 22504, 22506, 22508, 22514, 22516, and 22518, respectively;(226) SEQ ID NOS: 22604, 22606, 22608, 22614, 22616, and 22618, respectively;(227) SEQ ID NOS: 22704, 22706, 22708, 22714, 22716, and 22718, respectively;(228) SEQ ID NOS: 22804, 22806, 22808, 22814, 22816, and 22818, respectively;(229) SEQ ID NOS: 22904, 22906, 22908, 22914, 22916, and 22918, respectively;(230) SEQ ID NOS: 23004, 23006, 23008, 23014, 23016, and 23018, respectively; or(231) SEQ ID NOS: 23104, 23106, 23108, 23114, 23116, and 23118, respectively.

[0027] In particular exemplary embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of:(1) SEQ ID NOS: 104, 106, 108, 114, 116, and 118, respectively;(2) SEQ ID NOS: 204, 206, 208, 214, 216, and 218, respectively;(3) SEQ ID NOS: 304, 306, 308, 314, 316, and 318, respectively;(86) SEQ ID NOS: 8604, 8606, 8608, 8614, 8616, and 8618, respectively;(123) SEQ ID NOS: 12304, 12306, 12308, 12314, 12316, and 12318, respectively;(130) SEQ ID NOS: 13004, 13006, 13008, 13014, 13016, and 13018, respectively;(140) SEQ ID NOS: 14004, 14006, 14008, 14014, 14016, and 14018, respectively;(162) SEQ ID NOS: 16204, 16206, 16208, 16214, 16216, and 16218, respectively;(175) SEQ ID NOS: 17504, 17506, 17508, 17514, 17516, and 17518, respectively;(212) SEQ ID NOS: 21204, 21206, 21208, 21214, 21216, and 21218, respectively;(213) SEQ ID NOS: 21304, 21306, 21308, 21314, 21316, and 21318, respectively;(214) SEQ ID NOS: 21404, 21406, 21408, 21414, 21416, and 21418, respectively;(215) SEQ ID NOS: 21504, 21506, 21508, 21514, 21516, and 21518, respectively;(216) SEQ ID NOS: 21604, 21606, 21608, 21614, 21616, and 21618, respectively;(217) SEQ ID NOS: 21704, 21706, 21708, 21714, 21716, and 21718, respectively;(218) SEQ ID NOS: 21804, 21806, 21808, 21814, 21816, and 21818, respectively;(219) SEQ ID NOS: 21904, 21906, 21908, 21914, 21916, and 21918, respectively;(220) SEQ ID NOS: 22004, 22006, 22008, 22014, 22016, and 22018, respectively;(221) SEQ ID NOS: 22104, 22106, 22108, 22114, 22116, and 22118, respectively;(222) SEQ ID NOS: 22204, 22206, 22208, 22214, 22216, and 22218, respectively;(223) SEQ ID NOS: 22304, 22306, 22308, 22314, 22316, and 22318, respectively;(224) SEQ ID NOS: 22404, 22406, 22408, 22414, 22416, and 22418, respectively;(225) SEQ ID NOS: 22504, 22506, 22508, 22514, 22516, and 22518, respectively;(226) SEQ ID NOS: 22604, 22606, 22608, 22614, 22616, and 22618, respectively; or(227) SEQ ID NOS: 22704, 22706, 22708, 22714, 22716, and 22718, respectively;(228) SEQ ID NOS: 22804, 22806, 22808, 22814, 22816, and 22818, respectively;(229) SEQ ID NOS: 22904, 22906, 22908, 22914, 22916, and 22918, respectively;(230) SEQ ID NOS: 23004, 23006, 23008, 23014, 23016, and 23018, respectively; or(231) SEQ ID NOS: 23104, 23106, 23108, 23114, 23116, and 23118, respectively.

[0028] In further exemplary embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the amino acid sequences of:(212) SEQ ID NOS: 21204, 21206, 21208, 21214, 21216, and 21218, respectively;(213) SEQ ID NOS: 21304, 21306, 21308, 21314, 21316, and 21318, respectively;(214) SEQ ID NOS: 21404, 21406, 21408, 21414, 21416, and 21418, respectively;(215) SEQ ID NOS: 21504, 21506, 21508, 21514, 21516, and 21518, respectively;(216) SEQ ID NOS: 21604, 21606, 21608, 21614, 21616, and 21618, respectively;(217) SEQ ID NOS: 21704, 21706, 21708, 21714, 21716, and 21718, respectively;(218) SEQ ID NOS: 21804, 21806, 21808, 21814, 21816, and 21818, respectively;(219) SEQ ID NOS: 21904, 21906, 21908, 21914, 21916, and 21918, respectively;(220) SEQ ID NOS: 22004, 22006, 22008, 22014, 22016, and 22018, respectively;(221) SEQ ID NOS: 22104, 22106, 22108, 22114, 22116, and 22118, respectively;(222) SEQ ID NOS: 22204, 22206, 22208, 22214, 22216, and 22218, respectively;(223) SEQ ID NOS: 22304, 22306, 22308, 22314, 22316, and 22318, respectively;(224) SEQ ID NOS: 22404, 22406, 22408, 22414, 22416, and 22418, respectively;(225) SEQ ID NOS: 22504, 22506, 22508, 22514, 22516, and 22518, respectively;(226) SEQ ID NOS: 22604, 22606, 22608, 22614, 22616, and 22618, respectively;(227) SEQ ID NOS: 22704, 22706, 22708, 22714, 22716, and 22718, respectively;(228) SEQ ID NOS: 22804, 22806, 22808, 22814, 22816, and 22818, respectively;(229) SEQ ID NOS: 22904, 22906, 22908, 22914, 22916, and 22918, respectively;(230) SEQ ID NOS: 23004, 23006, 23008, 23014, 23016, and 23018, respectively; or(231) SEQ ID NOS: 23104, 23106, 23108, 23114, 23116, and 23118, respectively.

[0029] In other words, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 and VL amino acid sequences of any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36.

[0030] In some preferred embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 and VL amino acid sequences of an antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI- 58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI- 58131, ADI-58130_LCN30cQ, and ADI-59988.

[0031] In further preferred embodiments, the amino acid sequences of the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 may be identical to the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 and VL amino acid sequences of an antibody selected from the group consisting of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123,ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0032] In some embodiments, the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant of any of the anti-CoV-S antibodies disclosed herein, may possess one of the following structural features:(1) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 112;(2) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 212;(3) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 312;(4) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 412;(5) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 512;(6) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 612;(7) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 712;(8) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 802, and (b) the VL maycomprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 812;(9) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 912;(10) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1012;(11) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1112;(12) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1212;(13) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1312;(14) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1412;(15) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1512;(16) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1612;(17) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1702, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1712;(18) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1812;(19) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1912;(20) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2012;(21) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2112;(22) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2212;(23) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2312;(24) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2412;(25) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2512;(26) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2602, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2612;(27) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2712;(28) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2812;(29) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2912;(30) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3012;(31) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3112;(32) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3212;(33) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3312;(34) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3412;(35) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3502, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3512;(36) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3612;(37) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3712;(38) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3812;(39) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3912;(40) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4012;(41) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4112;(42) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4212;(43) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4312;(44) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4402, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO:4412;(45) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4512;(46) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4612;(47) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4712;(48) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4812;(49) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4912;(50) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5012;(51) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5112;(52) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5212;(53) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5302, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5312;(54) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5412;(55) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5512;(56) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5612;(57) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5712;(58) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5812;(59) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5912;(60) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6012;(61) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6112;(62) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6202, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6212;(63) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6312;(64) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6412;(65) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6512;(66) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6612;(67) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6712;(68) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6812;(69) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6912;(70) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7012;(71) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7102, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7112;(72) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7202, and (b) the VL comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7212;(73) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7312;(74) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7412;(75) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7512;(76) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7602, and (b) the VL comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7612;(77) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7712;(78) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7812;(79) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7912;(80) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8002, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8012;(81) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8112;(82) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8212;(83) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8312;(84) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8402, and (b) the VL nay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8412;(85) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8512;(86) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8612;(87) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8712;(88) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8812;(89) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8902, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8912;(90) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9012;(91) (a) the VH may comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9112;(92) (a) the VH may comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9212;(93) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9312;(94) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9412;(95) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9512;(96) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9612;(97) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9712;(98) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9802, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9812;(99) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9912;(100) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10012;(101) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10112;(102) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10212;(103) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10312;(104) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10412;(105) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10512;(106) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10612;(107) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10702, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10712;(108) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10812;(109) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10912;(110) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11012;(111) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11112;(112) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11212;(113) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11312;(114) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11412;(115) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11512;(116) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11602, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11612;(117) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11712;(118) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11812;(119) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11912;(120) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12012;(121) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12112;(122) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12212;(123) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12312;(124) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12412;(125) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12502, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12512;(126) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12612;(127) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12712;(128) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12812;(129) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12912;(130) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13012;(131) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13112;(132) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13212;(133) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13312;(134) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13402, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13412;(135) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13512;(136) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13612;(137) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13712;(138) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13812;(139) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13912;(140) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14012;(141) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14112;(142) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14212;(143) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14302, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14312;(144) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14412;(145) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14512;(146) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14612;(147) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14712;(148) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14812;(149) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14902, and (b) the VL comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14912;(150) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15012;(151) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15112;(152) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15202, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15212;(153) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15312;(154) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15412;(155) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15512;(156) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15612;(157) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15712;(158) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15812;(159) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15912;(160) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16012;(161) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16102, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16112;(162) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16212;(163) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16312;(164) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16412;(165) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16512;(166) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16612;(167) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16712;(168) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16812;(169) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16912;(170) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17002, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17012;(171) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17112;(172) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17212;(173) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17312;(174) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17412;(175) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17512;(176) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17612;(177) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17712;(178) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17812;(179) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17902, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17912;(180) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18012;(181) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18112;(182) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18212;(183) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18312;(184) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18412;(185) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18512;(186) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18612;(187) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18712;(188) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18802, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18812;(189) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18912;(190) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19012;(191) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19112;(192) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19202, and (b) the VL comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19212;(193) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19312;(194) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19412;(195) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19512;(196) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19612;(197) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19702, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19712;(198) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19812;(199) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19912;(200) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20012;(201) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20112;(202) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20212;(203) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20312;(204) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20412;(205) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20512;(206) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20602, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20612;(207) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20712;(208) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20812;(209) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20912;(210) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21012;(211) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21112;(212) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21212;(213) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21312;(214) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21412;(215) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21502, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21512;(216) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21612;(217) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21712;(218) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21812;(219) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21912;(220) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22012; or(221) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22112,(222) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22212;(223) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22312;(224) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22402, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22412;(225) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22512;(226) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22612; or(227) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22712;(228) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22812;(229) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22912;(230) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23012; or(231) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23112.

[0033] In some embodiments, the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant of any of the anti-CoV-S antibodies disclosed herein, may possess one of the following structural features:(1) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 102, and (b) the VL maycomprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 112;(2) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 212;(3) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 312;(86) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8612;(123) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12312;(130) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13012;(140) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14012;(162) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16212;(175) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97,98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17512.

[0034] In further embodiments:(212) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21212;(213) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21312;(214) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21412;(215) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21512;(216) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21612;(217) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21712;(218) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21812;(219) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21912;(220) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22002, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22012; or(221) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22112,(222) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22212;(223) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22312;(224) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22412;(225) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22512;(226) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22602, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22612;(227) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22712(228) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22812;(229) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22902, and (b) the VLmay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22912;(230) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23012; or.(231) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23112.

[0035] In further preferred embodiments:(217) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21702, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21712;(218) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21802, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21812;(219) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21902, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21912;(220) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22002, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22012; or(221) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22102, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22112,(222) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22202, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22212;(223) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22302, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22312;(224) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22402, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22412; or(225) (a) the VH may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22502, and (b) the VL may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22512.

[0036] In some embodiments, the present disclosure provides an isolated antibody, or antigen binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises at least one, e.g., two, three, four, five or six, of the following sequences:(a) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of X1X2FX3X4X5X6X7X8(SEQ ID NO: 23205), wherein Xi is F or Y, X2is T or S, X3is S or T, X4is S, R, G, H, T, A, or K, X5Is F or Y, X6is Y, A, D, G, P, or V, X7is M or I, and X8is H or N;(b) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of X1TFX2SYYX3X4(SEQ ID NO: 23206), wherein Xi is F or Y, X2is T or S, X3is M or I, and X4is H orN;(c) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FTFSSYYMN (SEQ ID NO: 23207);(d) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of SISX1DGYX2TYYPDSLKG (SEQ ID NO: 23208), wherein Xi is S or E and X2is N or S;(e) a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ARDFSGHTAXiAGTGFEY (SEQ ID NO: 23209), wherein Xi is W or V;(f) a light chain variable region (VL) comprising a VL CDR1 having a sequence ofTSGX 1 SNX2GAGYX3 VH (SEQ ID NO: 23210), wherein Xi is N or S, X2is I or V, and X3is D or Y;(g) a light chain variable region (VL) comprising a VL CDR2 having a sequence of GX1X2X3X4X5X6(SEQ ID NO: 23211), wherein Xi is A, S, or T, X2is S or T, X3is S, T, A, or N, X4is R, L, or T, X5is A, P, Q, H, or N, and Cb is T or S;(h) a light chain variable region (VL) comprising a VL CDR2 having a sequence of GX1SSX2X3S (SEQ ID NO: 23212), wherein Xi is S or A, X2is R or L, and X3is N, H, or Q;(i) a light chain variable region (VL) comprising a VL CDR2 having a sequence of GSSSRNS (SEQ ID NO: 23213); and(j) a light chain variable region (VL) comprising a VL CDR3 having a sequence of QSYDSSLSVLYXi (SEQ ID NO: 23214), wherein Xi is T or V.

[0037] In some embodiments, the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence ofARDLSGHTAXiAGTGPEY (SEQ ID NO: 23209), wherein Xi is W or V, and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QSYDSSLSVLYXi (SEQ ID NO: 23214), wherein Xi is T or V.

[0038] In other embodiments, the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ARDLSGHTAXiAGTGPEY (SEQ ID NO: 23209), wherein Xi is W or V; a VH CDR2 having a sequence of SISX1DGYX2TYYPDSLKG (SEQ ID NO: 23208), wherein Xi is S or E and X2is N or S; and a VH CDR1 having a sequence of X1TPX2SYYX3X4 (SEQ ID NO: 23206), wherein Xi is F or Y, X2 is T or S, X3 is M or I, and X4 is H or N; and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QSYDSSLSVLYXi (SEQ ID NO: 23214), wherein Xi is T or V; a VL CDR2 having a sequence of GX1SSX2X3S (SEQ ID NO: 23212), wherein Xi is S or A, X2 is R or L, and X3is N, H, or Q; and a VL CDR1 having a sequence of TSGX 1 SNX2GAGYX3 VH (SEQ ID NO: 23210), wherein Xi is N or S, X2 is I or V, and X3 is D or Y.

[0039] In some embodiments, the present disclosure provides an isolated antibody, or antigen binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises at least one, e.g., two, three, four, five or six, of the following sequences:(a) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of X1X2FX3X4X5X6X7X8(SEQ ID NO: 23205), wherein Xi is F or Y, X2is T or S, X3is S or T, X4is S, R, G, H, T, A, or K, X5Is F or Y, X6is Y, A, D, G, P, or V, X7is M or I, and X8is H or N;(b) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FTFSX1X2AMH (SEQ ID NO: 23215), wherein Xi is R or K and X2is F or Y;(c) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FTFSRFAMH (SEQ ID NO: 23216);(d) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of AINLNGDSXiYYTDSVRG (SEQ ID NO: 23217), wherein Xi is K or T;(e) a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of VKDGGYYDSSGPGH (SEQ ID NO: 23218);(f) a light chain variable region (VL) comprising a VL CDR1 having a sequence of RASX1NX2X3X4X5LA (SEQ ID NO: 23219), wherein Xi is E or Q, X2is I or V, X3is L, A, or N, X4is H or N, and X5is Y or W;(g) a light chain variable region (VL) comprising a VL CDR1 having a sequence of RASENIXiHYLA (SEQ ID NO: 23220), wherein Xi is L or A;(h) a light chain variable region (VL) comprising a VL CDR1 having a sequence of RASENILHYLA (SEQ ID NO: 23221);(i) a light chain variable region (VL) comprising a VL CDR2 having a sequence of X1X2X3X4RX5X6(SEQ ID NO: 23222), wherein Xi is D or E, X2is A, S, T, or V, X3is S or F, X4is S, A, T, K, N, or R; X5is A or V, and Cb is T, S, or P;(j) a light chain variable region (VL) comprising a VL CDR2 having a sequence of DX1SX2RAT (SEQ ID NO: 23223), wherein Xi is A, S, or V, X2is K or R;(k) a light chain variable region (VL) comprising a VL CDR2 having a sequence of DASRRAT (SEQ ID NO: 23224); and(l) a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQRXiNWPQN (SEQ ID NO: 23225), wherein Xi is A or S.

[0040] In some embodiments, the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of VKDGGYYDSSGPGH (SEQ ID NO: 23218), and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQRXiNWPQN (SEQ ID NO: 23225), wherein Xi is A or S.

[0041] In some embodiments, the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of VKDGGYYDSSGPGH (SEQ ID NO: 23218); a VH CDR2 having a sequence of AINLNGDSXiYYTDSVRG (SEQ ID NO: 23217), wherein Xi is K or T; and a VH CDR1 having a sequence of FTFS X1X2AMH (SEQ ID NO: 23215), wherein Xi is Ror K and X2 is F or Y; and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQRXiNWPQN (SEQ ID NO: 23225), wherein Xi is A or S; a VL CDR2 having a sequence of DXiS X2RAT (SEQ ID NO: 23223), wherein Xi is A, S, or V, X2 is K or R; and a VL CDR1 having a sequence of RASENIXiHYLA (SEQ ID NO: 23220), wherein Xi is L or A.

[0042] In some embodiments, the present disclosure provides an isolated antibody, or antigen binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises at least one, e.g., two, three, four, five or six, of the following sequences:(a) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FPFXiGTYMT (SEQ ID NO: 23226), wherein Xi is K or S;(b) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FX1FX2GX3X4MX5 (SEQ ID NO: 23227), wherein Xi is P or I, X2is K or S, X3is T or H, X4is W or Y, and X5 is T or S;(c) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of IIY SGGDTYY AD S VKG (SEQ ID NO: 23228);(d) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence ofX1X2Y SGGX3TYYADX4VX5G (SEQ ID NO: 23229), wherein Xi is V or I, X2is L or I, X3is D or S, X4is S or A, and X5 is K or Q;(e) a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ARDREMAIITERXiYGLDV (SEQ ID NO: 23230), wherein Xi is T or S;(f) a light chain variable region (VL) comprising a VL CDR1 having a sequence of SGGS SNIGSN S VN (SEQ ID NO: 23231);(g) a light chain variable region (VL) comprising a VL CDR1 having a sequence of SGX1X2X3NIX4SNX5VN (SEQ ID NO: 23232), wherein Xi G or S, X2is S or T, X3is S or A, X4is G or A, and X5 is S or G;(h) a light chain variable region (VL) comprising a VL CDR2 having a sequence of X1X2SQRPS (SEQ ID NO: 23233), wherein Xi is S or A and X2 is N or V;(i) a light chain variable region (VL) comprising a VL CDR2 having a sequence of X1X2X3X4RPS (SEQ ID NO: 23234), wherein Xi is G, S, or A, X2is N or V, X3is S or G, and X4is N or Q; and(j) a light chain variable region (VL) comprising a VL CDR3 having a sequence of AAWDD SLNTFRYV (SEQ ID NO: 23235).

[0043] In some embodiments, the present disclosure provides an isolated antibody, or antigen binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises at least one, e.g., two, three, four, five or six, of the following sequences:(a) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of GTFSSXiAIS (SEQ ID NO: 23236), wherein Xi is Y or D;(b) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of GX1FX2SX3X4X5X6 (SEQ ID NO: 23237), wherein Xi is T, S, or P, X2is S or T, X3is Y, F, or D, X4is V, G, or A, X5 is V, L, or I, and Cb is S or T;(c) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of GIIPIF VTANY AQKFQG (SEQ ID NO: 23238);(d) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of GIX1PIFX2TX3X4YAQKFQX5(SEQ ID NO: 23239), wherein Xi is I or M, X2is G or V, X3is A or T, X4is N or G, and X5is G or D;(e) a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ARGRMATIRGGQNYYYYY GMD V (SEQ ID NO: 23240);(f) a light chain variable region (VL) comprising a VL CDR1 having a sequence of QASQDISNYLN (SEQ ID NO: 23241);(g) a light chain variable region (VL) comprising a VL CDR1 having a sequence of QASQDIX1X2X3LN (SEQ ID NO: 23242), wherein Xi is S or R, X2is N or K, and X3is Y or C;(h) a light chain variable region (VL) comprising a VL CDR2 having a sequence of_DASNLET (SEQ ID NO: 23243);(i) a light chain variable region (VL) comprising a VL CDR2 having a sequence of X1X2SX3LX4X5 (SEQ ID NO: 23244), wherein Xi is V, A, S, T, D, E, K, or R, X2is A, V, or T, X3is S, N, T, or K, X4 is Q, E, K, or R, and X5 is S, N, or T;(j) a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQYDNLPLT (SEQ ID NO: 23245);(k) a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQX1X2X3LPX4T (SEQ ID NO: 23246), wherein Xi is Y or F, X2is D or E, X3is N or D, and X4 is L or I; and(l) a light chain variable region (VL) comprising a VL CDR3 having a sequence of QX1X2X3X4X5PX6X7(SEQ ID NO: 23247), wherein Xi is Q or H, X2is Y, A, or F, X3is D or E, X4is N, S, or D, X5is L, Y, or F, Cb is I, L, T, V, or F, and X7is T or A.

[0044] In some embodiments, the present disclosure provides an isolated antibody, or antigen binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises at least one, e.g., two, three, four, five or six, of the following sequences:(a) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FTFDDYAMH (SEQ ID NO: 23248);(b) a heavy chain variable region (VH) comprising a VH CDR1 having a sequence of FX1X2DDYAX3H (SEQ ID NO: 23249), wherein Xi is T or I, X2is F or L, and X3is M or V;(c) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of GISWNSGX1INYADSVX2G (SEQ ID NO: 23250), wherein Xi is T or S and X2is M or K;(d) a heavy chain variable region (VH) comprising a VH CDR2 having a sequence of GIX1WNSGX2X3X4YADSVX5G (SEQ ID NO: 23251), wherein Xi is S or T, X2is S, T, or Y, X3is I or L, X4is N or G, and X5is K or M;(e) a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ASDSNYRDYYYHYGMDV (SEQ ID NO: 23252);(f) a light chain variable region (VL) comprising a VL CDR1 having a sequence of RSSQSLLHSXiGYNYLD (SEQ ID NO: 23253), wherein Xi is N or Q;(g) a light chain variable region (VL) comprising a VL CDR2 having a sequence of LGSNRAS (SEQ ID NO: 23254);(h) a light chain variable region (VL) comprising a VL CDR2 having a sequence of X1X2X3X4RX5S (SEQ ID NO: 23255), wherein Xi is L or G, X2is G or N, X3is S or N, X4is N or E, and X5 is A or S;(i) a light chain variable region (VL) comprising a VL CDR3 having a sequence of MQALQTPRT (SEQ ID NO: 23256); and0 a light chain variable region (VL) comprising a VL CDR3 having a sequence ofMQX1X2X3X4X5X6X7T (SEQ ID NO: 23257), wherein Xi is A or S, X2is L or I, X3is Q or no amino acid, X4is Q or T, X5is T, P, or V, Cb is P or G, and X7is R, I, or V.

[0045] In some exemplary embodiments the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant, may be human, humanized, primatized or chimeric.

[0046] In some exemplary embodiments the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant, may be bispecific or multispecific.

[0047] In some exemplary embodiments the isolated antibody or antigen-binding antibody fragment, optionally an affinity-matured variant, may comprise at least one first antigen-binding domain (“ABD”) and at least one second ABD.

[0048] Here, the following features (a) and (b) may be met:(a) the first ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a first anti-CoV-S antibody selected from any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36; and / or(b) the second ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a second anti-CoV-S antibody selected from any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36.

[0049] Optionally, the first anti-CoV-S antibody may be same as the second anti-CoV-S antibody or may be different from the second anti-CoV-S antibody.

[0050] The first anti-CoV-S antibody and the second anti-CoV-S antibody may bind to the same or different coronavirus species. Optionally, the first CoV-S and the second CoV-S may be (i) both of SARS-CoV or (ii) both of SARS-CoV-2.

[0051] Further optionally, the first anti-CoV-S antibody may be same as the second anti-CoV-S antibody or may be different from the second anti-CoV-S antibody. Still further optionally, these antibodies may bind to the same or different epitopes on a CoV-S expressed by said SARS-CoV orSARS-CoV-2. Alternatively, the first anti-CoV-S antibody and the second anti-CoV-S antibody may bind to different coronaviruses, optionally wherein the first CoV-S and the second CoV-S are (i) SARS-CoV and of SARS-CoV-2 coronaviruses, respectively, or are (ii) SARS-CoV-2 and of SARS- CoV coronaviruses, respectively.

[0052] Furthermore, in some preferred embodiments, the following features (a) and (b) may be met:

[0053] (a) the first ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a first anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI- 58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI- 58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988; and

[0054] (b) the second ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a second anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-57983, ADI-57978, ADI-56868, ADI-56443, and ADI-56479.

[0055] In some embodiments, the bispecific or multispecific isolated antibody or antigen-binding antibody fragment may comprise at least one first ABD and at least one second ABD.

[0056] In certain embodiments,(a) the first ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a first anti-CoV-S antibody selected from any one of anti-CoV-S antibodies described herein and in FIGS. 1, 2 and 36, or an affinity-matured variant of any of the foregoing; and / or(b) the second ABD binds to an antigen which may not be a CoV-S, optionally wherein the antigen is a cytokine, a cytokine receptor, or an immunomodulatory polypeptide. In certain preferred embodiments, in (a), the first ABD may comprise the VH CDR1, the VH CDR2, the VH CDR3, the VL CDR1, the VL CDR2, and the VL CDR3 of a first anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI- 56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-57983, ADI-57978, ADI-56868, ADI-56443, and ADI-56479, particularly preferably selected from the group consisting of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126,ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI- 59988.

[0057] In some embodiments, the isolated antibody or antigen-binding antibody fragment may comprise a Fab, Fab’, F(ab’)2, scFv, sc(Fv)2, minibody, diabody, sdAb, BITE.

[0058] In some embodiments, the isolated antibody or antigen-binding antibody fragment may comprise a constant region or Fc region or at least one domain thereof.

[0059] In certain embodiments, the constant region or Fc region may comprise a mutation which impairs or enhances at least one effector function, optionally FcR binding, FcRn binding, complement binding, glycosylation, complement-dependent cytotoxicity (“CDC”), or antibody-dependent cellular cytotoxicity (“ADCC”).

[0060] In some embodiments, the constant or Fc region is primate derived, preferably human.

[0061] The human constant or Fc region optionally may be selected from a human IgGl, IgG2, IgG3 or IgG4 constant or Fc region which optionally may be modified, optionally such as by domain deletion or by introducing one or more mutations which impair or enhance at least one effector function.

[0062] The present disclosure further relates to chimeric antigen receptors (“CARs”) comprising at least one antibody or antigen-binding antibody fragment described herein.

[0063] The present disclosure further relates to antibody-drug conjugates (“ADCs”) comprising: (a) at least one antibody or antigen-binding antibody fragment described herein; and (b) a drug.

[0064] In some embodiments, the drug may be: (i) an antiviral drug, which is optionally, remdesivir, favipiravir, darunavir, nelfmavir, saquinavir, lopinavir or ritonavir; (ii) an antihelminth drug, which may be optionally ivermectin; (iii) an antiparasite drug, which may be optionally hydroxychloroquine, chloroquine, or atovaquone; (iv) antibacterial vaccine, which may be optionally the tuberculosis vaccine BCG; or (v) an anti-inflammatory drug, which may be optionally a steroid such as ciclesonide, a TNF inhibitor (e.g., adalimumab), a TNF receptor inhibitor (e.g., etanercept), an IL-6 inhibitor (e.g., clazakizumab), an IL-6 receptor inhibitor (e.g., toclizumab), or metamizole; (vi) an antihistamine drug, which may be optionally bepotastine; (vii) an ACE inhibitor, which may be optionally moexipril; (viii) a drug that inhibits priming of CoV-S, which may be optionally a serine protease inhibitor such as nafamostat; or (ix) a cytotoxic drug, which may be optionally daunorubicin, mitoxantrone, doxorubicin, cucurbitacin, chaetocin, chaetoglobosin, chlamydocin, calicheamicin, nemorubicin, cryptophyscin, mensacarcin, ansamitocin, mitomycin C, geldanamycin, mechercharmycin, rebeccamycin, safracin, okilactomycin, oligomycin, actinomycin, sandramycin, hypothemycin, polyketomycin, hydroxyellipticine, thiocolchicine, methotrexate, triptolide, taltobulin, lactacystin, dolastatin, auristatin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), telomestatin, tubastatin A, combretastatin, maytansinoid, MMAD, MMAF, DM1, DM4, DTT, 16-GMB-APA-GA, 17-DMAP-GA, JW 55, pyrrolobenzodiazepine, SN-38, Ro 5-3335,puwainaphycin, duocarmycin, bafilomycin, taxoid, tubulysin, ferulenol, lusiol A, fumagillin, hygrolidin, glucopiericidin, amanitin, ansatrienin, cinerubin, phallacidin, phalloidin, phytosphongosine, piericidin, poronetin, phodophyllotoxin, gramicidin A, sanguinarine, sinefungin, herboxidiene, microcolin B, microcystin, muscotoxin A, tolytoxin, tripolin A, myoseverin, mytoxin B, nocuolin A, psuedolaric acid B, pseurotin A, cyclopamine, curvulin, colchicine, aphidicolin, englerin, cordycepin, apoptolidin, epothilone A, limaquinone, isatropolone, isofistularin, quinaldopeptin, ixabepilone, aeroplysinin, arruginosin, agrochelin, or epothilone.

[0065] The present disclosure also relates to isolated nucleic acids encoding any of the antibodies or antigen-binding antibody fragments disclosed herein.

[0066] In some embodiments, the nucleic acid may comprise:(212) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21210, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21220;(213) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21310, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21320;(214) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21410, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21420;(215) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21510, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21520;(216) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21610, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21620;(217) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21710, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21720;(218) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21810, and / or (b) a nucleic acid sequence with atleast 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21820;(219) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21910, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 21920;(220) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22010, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22020;(221) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22110, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22120;(222) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22210, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22220;(223) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22310, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22320;(224) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22410, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22420;(225) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22510, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22520;(226) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22610, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22620;(227) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22710, and / or (b) a nucleic acid sequence with atleast 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22720;(228) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22810, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22820;(229) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22910, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 22920;(230) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 23010, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 23020; or(231) (a) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 23110, and / or (b) a nucleic acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 23120.

[0067] The present disclosure also relates to isolated cells which may comprise any of the nucleic acids disclosed herein.

[0068] In some embodiments the cell may be a bacterial, yeast, insect, fungal, or mammalian cell, optionally a human cell, further optionally a CHO or HEK cell.

[0069] In some embodiments the cell may be a human immune cell, optionally a T, NK, B or dendritic cell.

[0070] The present disclosure further relates to methods of expressing the antibody or antigen binding antibody fragment or the CAR disclosed herein.

[0071] In some embodiments, the method may comprise: (a) culturing the cell expressing an antibody or antigen-binding antibody fragment or CAR of the present disclosure under conditions that permit expression; and (b) optionally isolating the antibody or antigen-binding antibody fragment or the CAR from the cell or the culture medium containing the cell.

[0072] The present disclosure further relates to methods of identifying an antibody or an antigen binding antibody fragment which specifically binds to CoV-S.

[0073] In some embodiments, the method may comprise: (a) obtaining antisera and / or B cells obtained from a patient infected with SARS-CoV or SARS-CoV-2, optionally wherein the patient recovered from SARS-CoV or SARS-CoV-2 infection or the patient is a convalescent patient infected with SARS-CoV or SARS-CoV-2; (b) contacting the antisera and / or B cells with the CoV-S; and (c)isolating an antibody or antigen-binding fragment thereof which specifically bind to the CoV-S. Optionally, the CoV-S is the spike protein of SARS-CoV (“SARS-CoV-S”) or of SARS-CoV-2 (“SARS-CoV-2-S”). Further optionally, the CoV-S may comprise the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB: 6VSB_B) or SEQ ID NO: 5 (SARS-CoV- 2-S, 1273 amino acids, GenBank: QHD43416.1).

[0074] In some embodiments, the method may further detect that the antibody or antigen-binding fragment thereof which specifically binds to CoV-S neutralizes, blocks or inhibits coronavirus infectivity or coronavirus proliferation, optionally wherein the coronavirus is SARS-CoV or SARS- CoV-2.

[0075] In certain embodiments, the method may further detect whether the antibody or antigen binding antibody fragment thereof which specifically binds to the CoV-S binds to other coronaviruses, optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV- OC43, HCoV-229E, and HCoV-NL63.

[0076] In any of such detection methods, the method may further comprise determining the sequence of the antibody or antigen-binding antibody fragment thereof may be determined.

[0077] In some embodiments these sequences may be affinity-matured or mutated to enhance binding affinity and / or potentially increase specificity to a particular CoV-S.

[0078] The present disclosure further provides compositions comprising: (a) at least one antibody or antigen-binding antibody fragment of the present disclosure; and (b) a pharmaceutically acceptable carrier or excipient.

[0079] The present disclosure further provides methods of determining whether a subject has been infected with SARS-CoV or SARS-CoV-2 or another coronavirus by detecting whether a biological sample from the subject may comprise SARS-CoV-S protein or SARS-CoV-S-2 protein or another coronavirus S protein homologous thereto based on its immunoreaction with at least one antibody or antigen-binding antibody fragment disclosed herein. The sample may optionally be blood, plasma, lymph, mucus, urine, and / or feces. Optionally, the SARS-CoV S may comprise the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB: 6VSB_B),

[0080] Alternatively, the SARS-CoV-2 may comprise the amino acid sequence of SEQ ID NO: 5 (SARS-CoV-2-S, 1273 amino acids, GenBank: QHD43416.1).

[0081] Such determination methods optionally may comprise an ELISA or radioimmunoassay.

[0082] In such determination methods, the subject optionally may be human, a companion animal (e.g., a dog or cat), an agricultural animal, e.g, animals used in meat production, or may comprise an animal in a zoo, e.g. , a tiger or lion.

[0083] In such determination methods, the samples optionally may be collected at different times from the subject and the presence or absence or the level of SARS-CoV-S or SARS-CoV-S-2 or another coronavirus S protein homologous thereto may be detected in order to assess whether thesubject has recovered. Here, the SARS-CoV S may comprise the amino acid sequence of SEQ ID NO: 1 (SARS-CoV-S, 1288 amino acids, Accession# PDB: 6VSB_B), and optionally the SARS-CoV-2 may comprise the amino acid sequence of SEQ ID NO: 5 (SARS-CoV-2-S, 1273 amino acids, GenBank: QHD43416.1).

[0084] The present disclosure further provides methods of inducing an immune response against SARS-CoV or SARS-CoV-2 or another coronavirus, which may be selected from MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63, in a subject in need thereof

[0085] In some embodiments, the methods may comprise administering at least one antibody or antigen-binding antibody fragment of the present disclosure.

[0086] In some embodiments, the methods may comprise administering a cocktail of different antibodies or antigen-binding antibody fragments of the present disclosure, e.g., which bind to the same or different epitopes on the same or different CoV-Ss.

[0087] In certain embodiments, the immune response elicits immunoprotection, optionally prolonged, against at least one coronavirus, optionally SARS-CoV or SARS-CoV-2, further optionally against another coronavirus.

[0088] The present disclosure further provides methods of inhibiting or blocking infection of susceptible cells by SARS-CoV or SARS-CoV-2 or another coronavirus, such as MERS-CoV, HCoV- HKU1, HCoV-OC43, HCoV-229E, and HCoV-NL63, in a subject in need thereof.

[0089] In some embodiments, the method may comprise administering at least one antibody or antigen-binding antibody fragment, of the present disclosure, e.g., a cocktail as above-described.

[0090] The present disclosure further provides methods of treating infection by SARS-CoV or SARS-CoV-2 or another coronavirus optionally such as MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63, or treating a condition, symptom, disease, or disorder associated with said infection in a subject in need thereof.

[0091] In some embodiments, the method may comprise administering to the subject a therapeutically effective amount of at least one antibody or antigen-binding antibody fragment, an ADC or a CAR, of the present disclosure, e.g., a cocktail as above-described.

[0092] In some embodiments, the condition, symptom, disease, or disorder comprises at least one of bronchitis, pneumonia, respiratory failure, acute respiratory failure, organ failure, multi-organ system failure, pediatric inflammatory multisystem syndrome, acute respiratory distress syndrome, blood clot, a cardiac condition, myocardial injury, myocarditis, heart failure, cardiac arrest, acute myocardial infarction, dysrhythmia, venous thromboembolism, post-intensive care syndrome, shock, anaphylactic shock, cytokine release syndrome, septic shock, disseminated intravascular coagulation, ischemic stroke, intracerebral hemorrhage, microangiopathic thrombosis, psychosis, seizure, nonconvulsive status epilepticus, traumatic brain injury, stroke, anoxic brain injury, encephalitis, posterior reversible leukoencephalopathy, necrotizing encephalopathy, post-infectious encephalitis,autoimmune mediated encephalitis, acute disseminated encephalomyelitis, acute kidney injury, acute liver injury, pancreatic injury, immune thrombocytopenia, subacute thyroiditis, a gastrointestinal complication, aspergillosis, increased susceptibility to infection with another virus or bacteria, and / or a pregnancy-related complication.

[0093] The present disclosure also provides methods of preventing infection by SARS-CoV or SARS-CoV-2 or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 in a subject in need thereof

[0094] In some embodiments, the method may comprise administering to the subject a prophylactically effective amount of at least one antibody or antigen-binding antibody fragment, an ADC or a CAR, of the present disclosure, e.g., a cocktail as above-described.

[0095] The present disclosure also provides methods of preventing the need for a subject infected with SARS-CoV or SARS-CoV-2 or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 to be placed on a ventilator, or reducing the time that a subject infected with SARS-CoV or SARS-CoV-2 or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 is on a ventilator.

[0096] In some embodiments, the method may comprise administering to the subject a prophylactically or therapeutically effective amount of at least one antibody or antigen-binding antibody fragment, an ADC or a CAR, of the present disclosure, e.g., a cocktail as above-described.

[0097] The present disclosure provides methods of preventing the onset of pneumonia in a subject infected SARS-CoV or SARS-CoV-2 or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63, or treating pneumonia and / or the symptoms of pneumonia in a subject for a subject infected SARS-CoV or SARS-CoV-2 or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63.

[0098] In some embodiments, the method may comprise administering to the subject a prophylactically or therapeutically effective amount of at least one antibody or antigen-binding antibody fragment, an ADC or a CAR, of the present disclosure, e.g., a cocktail as above-described.

[0099] In any of such methods, the subject optionally may be human or may comprise a companion animal, agricultural animal or animal in a zoo.

[0100] Optionally the subject may have at least one risk factor which renders them more prone to a poor clinical outcome.

[0101] In certain embodiments, wherein the risk factors may comprise one or more of (i) advanced age such as over 55, 60 or 65 years old, (ii) diabetes, (iii) a chronic respiratory condition such as asthma, cystic fibrosis, another fibrotic condition, or COPD, (iv) obesity, (iv) hypertension, (v) a cardiac or cardiovascular condition, such as heart defects or abnormalities, (vi) a chronicinflammatory or autoimmune condition, e.g., lupus or multiple sclerosis, and (vii) an immunocompromised status which optionally may be caused by cancer, chemotherapy, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV infection or AIDS, or prolonged use of corticosteroids or other immunosuppressive medications.In certain embodiments, the subject may further be treated with at least one other drug. In certain embodiments, the method further comprises administering to the subject at least one other drug. Optionally, such one other drug may be: (i) an antiviral drug, optionally, remdesivir, favipiravir, darunavir, nelfmavir, saquinavir, lopinavir, or ritonavir; (ii) an antihelminth drug, optionally ivermectin; (iii) an antiparasitic drug, optionally hydroxychloroquine, chloroquine, or atovaquone;(iv) antibacterial vaccine, optionally the tuberculosis vaccine BCG; (v) an anti-inflammatory drug, optionally a steroid such as ciclesonide, a TNF inhibitor (e.g., adalimumab), a TNF receptor inhibitor (e.g., etanercept), an IL-6 inhibitor (e.g., clazakizumab), an IL-6 receptor inhibitor (e.g., tocilizumab), or metamizole; (vi) an antihistamine drug, optionally bepotastine; (vii) an ACE inhibitor, optionally moexipril; and / or (viii) a drug that inhibits priming of CoV-S, optionally a serine protease inhibitor, further optionally nafamostat.

[0102] In certain embodiments, the subject may further be treated with: (I) an antiviral agent, optionally, remdesivir, favipiravir, darunavir, nelfmavir, saquinavir, lopinavir, or ritonavir; and (II) at least one other drug. In certain embodiments, the method may further comprise administering to the subject (I) an antiviral agent, optionally, remdesivir, favipiravir, darunavir, nelfmavir, saquinavir, lopinavir, or ritonavir; and (II) at least one other drug. Optionally, the at least one other drug may be (i) an antihelminth drug, further optionally ivermectin; (ii) an antiparasitic drug, optionally hydroxychloroquine, chloroquine, or atovaquone; (iii) an antibacterial vaccine, which is optionally the tuberculosis vaccine BCG; or (iv) an anti-inflammatory drug, optionally a steroid such as ciclesonide, a TNF inhibitor (e.g., adalimumab), a TNF receptor inhibitor (e.g., etanercept), an IL-6 inhibitor (e.g., clazakizumab), an IL-6 receptor inhibitor (e.g., toclizumab), or metamizole; (v) an antihistamine drug, optionally bepotastine; (vi) an ACE inhibitor, optionally moexipril; and / or (vii) a drug that inhibits priming of CoV-S, which is optionally a serine protease inhibitor such as nafamostat.

[0103] In some embodiments, anti-CoV-S antibodies or antigen-binding antibody fragments of the present disclosure may be characterized by having a certain VH CDR3 sequences or having a VH CDR3 sequences that are similar to a certain VH CDR3.

[0104] In some embodiments, antibodies or antigen-binding antibody fragments of the present may comprise: (i) a VH and a VL or (ii) a VH, and the VH may comprise a CDR3 having the amino acid sequence of SEQ ID NO: 2108, 21708, 22208, 22408, 22608, or 22708.

[0105] In certain embodiments, antibodies or antigen-binding antibody fragments of the present may comprise a VH and a VL, and the VH may additionally comprise a CDR1 and a CDR3 having the amino acid sequence of SEQ ID NOS: 2104 and 2108, respectively, SEQ ID NOS: 21704 and 21708,respectively, SEQ ID NOS: 22204 and 22208, respectively, SEQ ID NOS: 22404 and 22408, respectively, SEQ ID NOS: 22604 and 22608, respectively, or SEQ ID NOS: 22704 and 22708, respectively.

[0106] In further embodiments, antibody or antigen-binding antibody fragment of the present may comprise (I) a VH and a VL or (II) a VH, and the amino acid sequence of the VH CDR3 may be: (i) identical to the amino acid sequence of SEQ ID NO: 1508 or differ from SEQ ID NO: 1508 by 1, 2, or 3 amino acids; (ii) identical to the amino acid sequence of SEQ ID NO: 1308 or differ from SEQ ID NO: 1308 by 1, 2, or 3 amino acids; (iii) identical to the amino acid sequence of SEQ ID NO: 808 or differ from SEQ ID NO: 808 by 1, 2, or 3 amino acids; (iv) identical to the amino acid sequence of SEQ ID NO: 108 or differ from SEQ ID NO: 108 by 1, 2, or 3 amino acids; (v) identical to the amino acid sequence of SEQ ID NO: 2108 or differ from SEQ ID NO: 2108 by 1, 2, or 3 amino acids; (vi) identical to the amino acid sequence of SEQ ID NO: 108 or differs from SEQ ID NO: 108 by 1, 2, or 3 amino acids; (vii) identical to the amino acid sequence of SEQ ID NO: 208 or differs from SEQ ID NO: 208 by 1, 2, or 3 amino acids; (viii) identical to the amino acid sequence of SEQ ID NO: 308 or differs from SEQ ID NO: 308 by 1, 2, or 3 amino acids; (ix) identical to the amino acid sequence of SEQ ID NO: 8608 or differs from SEQ ID NO: 8608 by 1, 2, or 3 amino acids; (x) identical to the amino acid sequence of SEQ ID NO: 12308 or differs from SEQ ID NO: 12308 by 1, 2, or 3 amino acids; (xi) identical to the amino acid sequence of SEQ ID NO: 13008 or differs from SEQ ID NO: 13008 by 1, 2, or 3 amino acids; (xii) identical to the amino acid sequence of SEQ ID NO: 14008 or differs from SEQ ID NO: 14008 by 1, 2, or 3 amino acids; (xiii) identical to the amino acid sequence of SEQ ID NO: 16208 or differs from SEQ ID NO: 16208 by 1, 2, or 3 amino acids; (xiv) identical to the amino acid sequence of SEQ ID NO: 17508 or differs from SEQ ID NO: 17508 by 1, 2, or 3 amino acids; (xv) identical to the amino acid sequence of SEQ ID NO: 21708 or differs from SEQ ID NO: 21708 by 1, 2, or 3 amino acids; (xvi) identical to the amino acid sequence of SEQ ID NO:22208 or differs from SEQ ID NO: 22208 by 1, 2, or 3 amino acids; (xvii) identical to the amino acid sequence of SEQ ID NO: 22408 or differs from SEQ ID NO: 22408 by 1, 2, or 3 amino acids; (xviii) identical to the amino acid sequence of SEQ ID NO: 22608 or differs from SEQ ID NO: 22608 by 1,2, or 3 amino acids; or (xix) identical to the amino acid sequence of SEQ ID NO: 22708 or differs from SEQ ID NO: 22708 by 1, 2, or 3 amino acids; or (xx) identical to the amino acid sequence of SEQ ID NO: 23008 or differs from SEQ ID NO: 23008 by 1, 2, or 3 amino acids.

[0107] In one embodiment, the anti-CoV-S antibodies or antigen-binding antibody fragment may comprise the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI- 55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-57983, ADI-57978, ADI-56868,ADI-56443, and ADI-56479, optionally of an anti-CoV-S antibody selected from the group consisting of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI- 58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI- 58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988, and further optionally of an anti-CoV-S antibody selected from the group consisting of ADI-57983 (with primer mutation), ADI- 57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-58120, ADI-58121, ADI- 58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI- 58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0108] In some embodiments, the antibody or antigen-binding antibody fragment may specifically compete with another antibody or antigen-binding antibody fragment that may comprise the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-55688, ADI-55689, ADI-55690, ADI-55951, ADI-55993, ADI-56000, ADI-56010, ADI-56032, ADI-56046, ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, or ADI-59988, and preferably of ADI-57983 (with primer mutation), ADI- 57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-56443 (with primer mutation), ADI-56479 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, or ADI-59988, optionally of ADI-57983 (with primer mutation), ADI-57978 (with primer mutation), ADI-56868 (with primer mutation), ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0109] In certain embodiments, antibody or antigen-binding antibody fragment of the present disclosure may comprise an Fc region. The Fc region may comprise a wild type sequence or a variant sequence and optionally may comprise an amino acid sequence of SEQ ID NOs: 11, 12, 13, 14, 15,16, or 17.

[0110] In certain embodiments, the isolated antibody or antigen-binding antibody fragment may bind to the SI subunit of SARS-CoV-S or of SARS-CoV-2-S.

[0111] In certain embodiments, the isolated antibody or antigen-binding antibody fragment may bind to the receptor binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-S or of SARS- CoV-2-S.

[0112] In certain embodiments, the isolated antibody or antigen-binding antibody fragment may bind to the ACE2 -binding motif of SARS-CoV-S or of SARS-CoV-2-S and optionally further binds to the epitope of the antibody CR3022.

[0113] In further embodiments, the isolated antibody or antigen-binding antibody fragment may compete with ACE2.

[0114] In further embodiments, the isolated antibody or antigen-binding antibody fragment may compete with: (i) ACE2 and the antibody CR3022; or (ii) ACE2 but not the antibody CR3022. In certain embodiments, the isolated antibody or antigen-binding antibody fragment (a) may bind to the S protein of SARS-CoV and / or of SARS-CoV-2; and (b) may not bind to any of the S proteins of HCoV-229E, HCoV-HKUl, HCoV-NL63, and HCoV-OK43.

[0115] In certain embodiments, the isolated antibody or antigen-binding antibody fragment may (a) bind to the S protein of SARS-CoV and / or of SARS-CoV-2; and also (b) bind to the S protein of at least one of HCoV-229E, HCoV-HKUl, HCoV-NL63, and HCoV-OK43.

[0116] In further embodiments, the isolated antibody or antigen-binding antibody fragment may neutralize SARS-CoV and / or SARS-CoV-2.

[0117] In further embodiments, the isolated antibody or antigen-binding antibody fragment may neutralize SARS-CoV and / or SARS-CoV-2 at 100 nM in vitro.

[0118] In further embodiments, the isolated antibody or antigen-binding antibody fragment may neutralize SARS-CoV and / or SARS-CoV-2 at: (i) an IC50 of about 100 nM or lower, of about 50 nM or lower, of about 20 nM or lower, of about 10 nM or lower, of about 5 nM or lower, of about 2 nM or lower, of about 1 nM or lower, of about 500 pM or lower, of about 200 pM or lower, of about 100 pM or lower, of about 50 pM or lower, of about 20 pM or lower, of about 10 pM or lower, of about 5 pM or lower, of about 2 pM or lower, or of about 1 pM or lower; and / or (ii) an IC50 of about 500 ng / mL or lower, of about 200 ng / mL or lower, of about 100 ng / mL or lower, of about 50 ng / mL or lower, of about 20 ng / mL or lower, of about 10 ng / mL or lower, of about 20 ng / mL or lower, of about 10 mg / mL or lower, of about 5 ng / mL or lower, of about 2 ng / mL or lower, or of about 1 ng / mL or lower, in vitro, optionally as measured by any of the neutralization assays described in the Examples herein.

[0119] In further embodiments, the isolated antibody or antigen-binding antibody fragment may bind to CoV-S (S protein of any CoV, such as but not limited to SARS-CoV-S and / or SARS-CoV-2-S) with a KD value of: (i) 100 nM or lower; (ii) 10 nM or lower; (iii) 1 nM or lower; (iv) 100 pM or lower; (v) 10 pM or lower; (vi) 1 pM or lower; or (vii) 0.1 pM or lower.

[0120] In some embodiments, the antibody, or antigen-binding fragment thereof, is administered intravenously. In other embodiments, the antibody, or antigen-binding fragment thereof, is administered intramuscularly.

[0121] In some embodiments, the antibody, or antigen-binding fragment thereof, is administered at a dose of about 100 mg to about 2000 mg, about 200 mg to about 1500 mg, about 300 mg to about 600 mg, about 500 mg to about 1200 mg, or about 300 mg to about 1200 mg. In some embodiments, the antibody, or antigen-binding fragment thereof, is administered at a dose of about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg or about 2000 mg.

[0122] In some embodiments, the antibody, or antigen-binding fragment thereof, is administered at a dose of about 300 mg intramuscularly, about 500 mg intravenously, about 600 mg intramuscularly, or about 1200 mg intravenously.

[0123] In one embodiment, the antibody, or antigen-binding fragment thereof, is administered once. In one embodiment, the antibody, or antigen-binding fragment thereof, is administered weekly. In another embodiment, the antibody, or antigen-binding fragment thereof, is administered daily, weekly, every two weeks, monthly, or every two months. In one embodiment, the antibody, or antigen-binding fragment thereof, is administered weekly for about four weeks, once weekly for about a month, weekly for about 5 weeks, weekly for about 6 weeks, weekly for about 7 weeks, or weekly for about two months.

[0124] In one aspect, the present disclosure also relates to kits comprising: (a) at least one isolated antibody or antigen-binding antibody fragment disclosed herein; and (b) an instruction for using the antibody or antigen-binding antibody fragment.

[0125] In some embodiments, the kit may be for use in: (i) determining whether a CoV is present in a subject; (ii) diagnosing whether a subject has CoV infection; (iii) predicting whether a CoV vaccine will elicit a protective immune response; or (iv) predicting whether a CoV vaccine will elicit a neutralizing antibody response.

[0126] In one aspect, provided herein are methods of predicting the in vivo efficacy of an anti-CoV-S antibody or antigen-binding antibody fragment in preventing or treating CoV infection.

[0127] In some embodiments, the method may comprise: (a) providing at least one first test subject and at least one second subject or a cell sample derived from at least one first test subject and at least one second subject; (b) administering the antibody or antigen-binding antibody fragment to said at least one first test subject and said at least one second subject or contacting a cell sample from said first and second subject with the antibody or antigen-binding antibody fragment; (c) infecting said at least one first test subject and said at least one second subject with CoV or pseudo CoV or a cell sample obtained from said at least one first test subject and said at least one second subject with CoV or pseudo CoV ; (d) determining whether administration of the antibody or antigen-binding antibody fragment in (b) results in one or more of the following compared to a suitable control: (I) reduction in a CoV-associated symptom; (II) reduction in the CoV viremia; (III) increase in the survival; (IV)increase in the body weight; or (V) reduced infection of cells or virus proliferation in cells of the tested cell sample compared to a control cell sample not contacted with the antibody or antigen binding antibody fragment.

[0128] In some embodiments, the method may comprise: (a) providing at least one first cell sample and at least one second cell sample; (b) contacting the at least one first cell sample with the antibody or antigen-binding antibody fragment; (c) infecting said at least one first cell sample and at least one second cell sample with CoV or pseudo CoV; (d) determining whether the antibody or antigen binding antibody fragment results in one or more of the following compared to a suitable control: (I) increase in the cell survival; (II) reduced infection of cells; (III) reduced virus proliferation; (IV) reduced cell stress or death markers; or (V) reduced inflammatory cytokines, in cells of the tested cell sample compared to a control cell sample not contacted with the antibody or antigen-binding antibody fragment.

[0129] In some embodiments, the method may comprise: (a) providing at least one first test subject and at least one second subject or a cell sample derived from at least one first test subject and at least one second subject; (b) infecting said at least one first test subject and said at least one second subject with CoV or pseudo CoV or a cell sample derived from at least one first test subject and at least one second subject; (c) administering the antibody or antigen-binding antibody fragment to said at least one second subject or contacting a cell sample derived from at least one first test subject and at least one second subject with the antibody or antigen-binding antibody fragment; (d) determining whether administration of the antibody or antigen-binding antibody fragment in (c) results in one or more of the following: (I) reduction in a CoV-associated symptom; (II) reduction in the CoV viremia; (III) increase in the survival;(IV) increase in the body weight; or (V) reduced infection of cells or virus proliferation in cells in the tested cell sample compared to a control cell sample not contacted with the antibody or antigen-binding antibody fragment.

[0130] In some embodiments, the method may comprise: (a) providing at least one first cell sample and at least one second cell sample; (b) infecting said at least one first cell sample and at least one second cell sample with CoV or pseudo CoV; (c) contacting the at least one first cell sample with the antibody or antigen-binding antibody fragment; (d) determining whether the antibody or antigen binding antibody fragment results in one or more of the following compared to a suitable control: (I) increase in the cell survival; (II) reduced infection of cells; (III) reduced virus proliferation; (IV) reduced cell stress or death markers; or (V) reduced inflammatory cytokines, in cells of the tested cell sample compared to a control cell sample not contacted with the antibody or antigen-binding antibody fragment.

[0131] In one aspect, provided herein are methods of screening for an antibody or antigen-binding antibody fragment that binds to a CoV or CoV-S, the method comprising whether an antibody or antigen-binding antibody fragment comprising 1, 2, 3, 4, 5, or 6 CDRs of any of the antibodiesdisclosed herein may comprise one or more of the following features: (i) binds to the S protein of a CoV; (ii) binds to the SI subunit of CoV-S; (iii) binds to the RBD of CoV-S; (iv) binds to the NTD of CoV-S; (v) binds to the ACE2 -binding motif of CoV-S; (vi) competes with ACE2; (vii) competes with the antibody CR3022; (viii) neutralizes one or more of SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-HKUl, HCoV-NL63, or HCoV-OK43 or variants thereof; (ix) neutralizes a pseudovirus of one or more of SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-HKUl, HCoV-NL63, or HCoV-OK43 or variants thereof; (x) results in reduced infection of cells or virus proliferation in cells in a susceptible tested cell sample compared to a control cell sample not contacted with the antibody or antigen-binding antibody fragment; or (xi) prevents or treats CoV infection in vivo. During the screening, any of the antibodies disclosed herein and / or an antibody comprising one or more of the CDRs of the antibodies disclosed herein may be used as a candidate antibody or a control antibody.

[0132] In one aspect, the present disclosure also relates to compositions comprising at least one affinity-matured first anti-CoV-S antibody or antigen-binding antibody fragment and a pharmaceutically acceptable carrier or excipient.

[0133] In some embodiments, the at least one first antibody or antigen-binding antibody fragment may comprise: a VH comprising a VH CDR1, a VH CDR2, a VH CDR3; and a VL, comprising a VL CDR1 a VL CDR2, a VL CDR3, and the amino acid sequences of said VH CDR1, said VH CDR2, said VH CDR3, said VL CDR1, said VL CDR2, and said VL CDR3 are identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-58120, ADI- 58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI- 58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI-59988.

[0134] In particular embodiments, the VH and VL of said first antibody or antigen-binding antibody fragment may be the VH and VL, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-58120, ADI-58122, ADI-58124, ADI-58126, ADI-58128, ADI-58130, ADI-58131, and ADI-58130_LCN30cQ.

[0135] In some embodiments, the first antibody or antigen-binding antibody fragment may comprise an L c region, optionally wherein the F c region may comprise an amino acid sequence of SEQ ID NOs: 11, 12, 13, 14, 15, 16, or 17.

[0136] In one embodiment, the HC and LC of the first antibody or antigen-binding antibody fragment are the HC and LC, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI-58130_LCN30cQ, and ADI- 59988.

[0137] In certain embodiments, the composition may further comprise at least one second antibody or antigen-binding antibody fragment comprising a VH comprising a VH CDR1, a VH CDR2, a VH CDR3 and a VL, comprising a VL CDR1 a VL CDR2, a VL CDR3. In particular embodiments, the amino acid sequences of said VH CDR1, said VH CDR2, said VH CDR3, said VL CDR1, said VL CDR2, and said VL CDR3 may be identical to the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively, of an anti-CoV-S antibody selected from the group consisting of ADI-58120, ADI-58121, ADI-58122, ADI-58123, ADI-58124, ADI-58125, ADI-58126, ADI-58127, ADI-58128, ADI-58129, ADI-58130, ADI-58131, ADI- 58130_LCN30cQ, and ADI-59988.

[0138] In some embodiments, the second antibody or antigen-binding antibody fragment may comprise an Fc region, optionally wherein the Fc region may comprise an amino acid sequence of SEQ ID NOs: 11, 12, 13, 14, 15, 16, or 17.

[0139] In particular embodiments, the antibody or antigen-binding antibody fragment according to the present disclosure may comprise:(217) a HC comprising the amino acid sequence of SEQ ID NO: 21701 and a LC comprising the amino acid sequence of SEQ ID NO: 21711;(218) a HC comprising the amino acid sequence of SEQ ID NO: 21801 and a LC comprising the amino acid sequence of SEQ ID NO: 21811;(219) a HC comprising the amino acid sequence of SEQ ID NO: 21901 and a LC comprising the amino acid sequence of SEQ ID NO: 21911;(220) a HC comprising the amino acid sequence of SEQ ID NO: 22001 and a LC comprising the amino acid sequence of SEQ ID NO: 22011;(221) a HC comprising the amino acid sequence of SEQ ID NO: 22101 and a LC comprising the amino acid sequence of SEQ ID NO: 22111;(222) a HC comprising the amino acid sequence of SEQ ID NO: 22201 and a LC comprising the amino acid sequence of SEQ ID NO: 22211;(223) a HC comprising the amino acid sequence of SEQ ID NO: 22301 and a LC comprising the amino acid sequence of SEQ ID NO: 22311;(224) a HC comprising the amino acid sequence of SEQ ID NO: 22401 and a LC comprising the amino acid sequence of SEQ ID NO: 22411;(225) a HC comprising the amino acid sequence of SEQ ID NO: 22501 and a LC comprising the amino acid sequence of SEQ ID NO: 22511;(226) a HC comprising the amino acid sequence of SEQ ID NO: 22601 and a LC comprising the amino acid sequence of SEQ ID NO: 22611;(227) a HC comprising the amino acid sequence of SEQ ID NO: 22701 and a LC comprising the amino acid sequence of SEQ ID NO: 22711;(228) a HC comprising the amino acid sequence of SEQ ID NO: 22801 and a LC comprising the amino acid sequence of SEQ ID NO: 22811;(229) a HC comprising the amino acid sequence of SEQ ID NO: 22901 and a LC comprising the amino acid sequence of SEQ ID NO: 22911;(230) a HC comprising the amino acid sequence of SEQ ID NO: 23001 and a LC comprising the amino acid sequence of SEQ ID NO: 23011; or(231) a HC comprising the amino acid sequence of SEQ ID NO: 23101 and a LC comprising the amino acid sequence of SEQ ID NO: 23111.

[0140] In further embodiments, the composition according to the present disclosure may comprise: (A) at least one first antibody or antigen-binding antibody fragment selected from the group consisting of the antibodies or antigen-binding antibody fragments comprising the HC and LC combination of (217)-(231) as described above; and (B) a pharmaceutically acceptable carrier or excipient.

[0141] In yet further embodiments, the composition may additionally comprise at least one second antibody or antigen-binding antibody fragment selected from the group consisting of the antibodies or antigen-binding antibody fragments comprising the HC and LC combination of (217)-(231) as described above.

[0142] Additionally, the present disclosure further encompasses isolated antibodies and antigen binding antibody fragments thereof, which competes for binding with any one or more of the anti- CoV antibodies or antigen-binding antibody fragments thereof as described herein.

[0143] The present disclosure also encompasses isolated antibodies or antigen-binding antibody fragments thereof, which bind the same epitope as any one or more of the anti-CoV antibodies or antigen-binding antibody fragments thereof as described herein.

[0144] The present disclosure further encompasses affinity matured variants of any one or more of the anti-CoV antibodies or antigen-binding antibody fragments thereof as described herein.

[0145] In one aspect, disclosed herein is a method of treating a coronavirus infection by SARS-CoV, SARS-CoV-2, and / or another coronavirus optionally selected from the group consisting of MERS- CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody, or antigen-binding antibody fragment thereof, which binds the same epitope as ADI-58125, and / or which competes for binding with ADI-58125.

[0146] In one aspect, disclosed herein is a method of decreasing the risk of mortality, hospitalization, mechanical ventilation, or a combination thereof in a patient infected by SARS-CoV, ARS-CoV-2, and / or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV- HKU1, HCoV-OC43, HCoV-229E, and HCoV-NL63, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody, or antigen-binding antibodyfragment thereof, which binds the same epitope as ADI-58125, and / or which competes for binding with ADI-58125.

[0147] In another aspect, disclosed herein is a method of preventing infection of a subject by SARS- CoV, SARS-CoV-2, and / or another coronavirus optionally selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody, or antigen binding antibody fragment thereof, which binds the same epitope as ADI-58125, and / or which competes for binding with ADI-58125.

[0148] In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55688. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55689. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55690. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55691. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55692. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55693. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55694. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55695. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55696. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55697. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55698. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55699. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55700. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55701. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55702. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55703. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55704. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55705. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55706. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55707. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55708. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55709. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55710. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55711. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55712. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55713. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55714. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55715. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55716. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55717. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55718. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55719. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55721. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55722. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55723. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55724. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55725. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55726. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55727. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55728. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55729. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55730. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55731. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55732. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55733. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55734. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55735. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55736. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55737. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55738. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55739. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55740. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55741. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55742. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55743. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55744. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55745. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55746. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55747. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55748. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55749. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55750. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55751. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55752. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55753. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55754. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55755. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55756. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55757. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55758. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55720. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55760. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55761. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55762. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55763. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55765. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55766. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55767. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55769. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55770. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55771. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55775. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55776. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55777. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55950. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55951. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig.36 is ADI-55952. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55953. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55954. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55955. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55956. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55957. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55958. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55959. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55960. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55961. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55962. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55963. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55964. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55965. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55966. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55967. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55968. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55969. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55970. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55972. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55973. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55974. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55975. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55976. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55977. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55978. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55979. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55980. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55981. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55982. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55984. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1,Fig. 2 or Fig. 36 is ADI-55986. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55988. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55989. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55990. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55992. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55993. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55994. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55995. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55996. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55997. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 55998. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-55999. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56000. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56001. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56002. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56003. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56004. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56005 ADI-56006. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56007. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56008. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56009. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56010. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56011. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56012. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56013. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56014. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56015. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56016. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56017. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56018. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56019. In one embodiment, the antibody, or antigen-binding fragmentthereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56020. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56021. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56022. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56023. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56024. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56025. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56026. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56027. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56028. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56029. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56030. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56031. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56032. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56033. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56034. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56035. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56037. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56038. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56039. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56040. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56041. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56042. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56043. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56044. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56045. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56046. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56047. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56048. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56049. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56050. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56051. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56052. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56053. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56054. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56055. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56056. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56057. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56058. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56059. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56061. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56062. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56063. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56064. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56065. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56066. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56067. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56068. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56069. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56070. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56071. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56072. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56073. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56074. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56075 ADI-56076. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56078. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56079. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56080. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56081. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 56082. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56083. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56084. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56443. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-56479. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58120. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58121. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 58122. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58123. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58124. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58125. In one embodiment, the antibody, or antigen binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58126. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58127. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58128. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI- 58129. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58130. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58131. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-58130_LCN30cQ. In one embodiment, the antibody, or antigen-binding fragment thereof, of Fig. 1, Fig. 2 or Fig. 36 is ADI-59988.BRIEF DESCRIPTION OF THE DRAWINGS

[0149] FIGS. 1A-1I provide the SEQ ID NOs assigned to the respective VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VH CDR3, and VH FR4 amino acid sequences, the respective VH amino acid sequences, and the respective VH-encoding nucleic acid sequences for 211 antibodies as indicated.

[0150] FIGS. 2A-2I provide the SEQ ID NOs assigned to the respective VL FR1, VL CDR1, VL FR2, VL CDR2, VL FR3, VL CDR3, and VL FR4 amino acid sequences, the respective VL amino acid sequences, and the respective VH-encoding nucleic acid sequences for 211 antibodies as indicated.

[0151] FIGS. 3A-3E provide the germline origin of the VH and VL of each of the 211 antibodies.

[0152] FIGS. 4A-4I provide the number of nucleotide substitutions in the VH-encoding and VL- encoding sequences as compared to the germline sequences and the number of amino acid alterations in the VH and VL polypeptide sequences as compared to the germline-encoded VH and VL sequences, for each of the antibodies. Eight antibodies were not analyzed (in this and some of other studies) due to the high sequence similarity to another antibody within the 211 antibodies, and were shown as blank.

[0153] FIGS. 5A-5C provide the B cell isotype of the 211 antibodies.

[0154] FIGS. 6A-6E provide the summary of SARS-CoV-2-S-binding B cell isolation and determination of the germline origin and isotype of each of the isolated antibodies. FIG. 6A shows the frequency of SARS-CoV-2 S-reactive B cells in VRC#202367 (a convalescent SARS-CoV donor) and a negative control SARS-CoV naive donor. Fluorescence activated cell sorting (FACS) plots shown are gated on CD19+CD20+IgD—IgM—B cells. SARS-CoV-2 S was labeled with two different colors to reduce background binding. FIG. 6B shows binding of 315 isolated antibodies to SARS- CoV -2 S, as determined by BLI. The solid line indicates the threshold used for designating binders (0.1 RUs). FIG. 6C shows clonal lineage analysis. Each lineage is represented as a segment proportional to the lineage size. Antibodies that utilize VH1-69 / VK2-30 germline gene pairing are shown in blue. Other germlines are shown in dark gray. The total number of isolated antibodies is shown in the center of the pie. Clonal lineages were defined based on the following criteria: identical VH and VL germline gene, identical VH CDR3 length, and VH CDR3 amino acid identity >80%. FIG. 6D shows the load of somatic mutations, expressed as number of nucleotide substitutions in VH, in unique antibodies and members of expanded clonal lineages. FIG. 6E shows the percentage of antibodies having the IgA+ isotype and antibodies having the IgG+ isotype. Proportion of SARS- CoV -2-S-binding antibodies derived from IgG+and IgA+B cells, as determined by index sorting. Statistical comparisons were made using the Mann-Whitney test (**** p < 0.0001). Red bars indicate medians. RU, response unit; VH, variable region of the heavy chain.

[0155] FIGS. 7A-7I show part of the results from the binding assays in Example 2. The KD [M], kon[M-1s1], k0ff[s1], and Binding Response (nm) for the S protein of SARS-CoV and SARS-CoV-2, for the 211 antibodies, are provided.

[0156] FIGS. 8A-8E show part of the results from the binding assays in Example 3. The KD [M], kon[M1s1], k0ff[s1], and Binding Response (nm) for the S protein of HCoV-229E (an endemic / seasonal / circulating species), for the 211 antibodies, are provided.

[0157] FIGS. 9A-9E show part of the results from the binding assays in Example 3. The KD [M], kon[M1s1], k0ff[s1], and Binding Response (nm) for the S protein of HCoV-HKUl (an endemic / seasonal / circulating species), for the 211 antibodies, are provided.

[0158] FIGS. 10A-10E show part of the results from the binding assays in Example 3. The KD [M], kon[M1s1], k0ff[s1], and Binding Response (nm) for the S protein of HCoV-NL63 (an endemic / seasonal / circulating species), for the 211 antibodies, are provided.

[0159] FIGS. 11A-11E show part of the results from the binding assays in Example 3. The KD [M], kon[M1s1], k0ff[s1], and Binding Response (nm) for the S protein of HCoV-OC43 (an endemic / seasonal / circulating species), for the 211 antibodies, are provided.

[0160] FIGS. 12A-12I provide a summary of the binding affinity results from FIGS. 7-11. When an antibody showed a binding response (nm) value of 0.1 or higher for a target, the antibody was considered as a binder (shown as Wes”) to that target. Note that antibodies with a binding responsevalue such as 0.099 or 0.098 that can be round to 0.1 were also considered as binders and shown as “Yes”. When an antibody showed a binding response (nm) value of < 0.1 for a target in FIGS. 7-11, the antibody was considered as a non-binder (shown as “No”) for that target. When an antibody was Wes” for SARS-CoV-S and / or SARS-CoV-2-S but “No” for all of S protein of the circulating CoV species (HCoV-229E, HCoV-HKU, HCoV-NL63, and HCoV-OK43), the antibody is classified as “SARS1-2 specific”. When an antibody was Wes” for SARS-CoV-S and / or SARS-CoV-2-S and also Wes” for the S protein of one or more the circulating CoV species (HCoV-229E, HCoV-HKU, HCoV-NL63, and HCoV-OK43), the antibody is classified as “Broad”.

[0161] FIGS. 13A-13C provide the polyspecificity score and polyspecificity category for each antibody.

[0162] FIG. 13D provides poly specificity of broadly cross-reactive (“Broad”) and SARS- CoV / SARS-CoV-2-specific (“SARS1 / 2 only”) antibodies, as determined using a previously described assay (Xu et al, Protein Engineering, Design and Selection 26(10), 663-670 (2013)). Thresholds for high, medium, low, and no polyspecificity are indicated by dashed lines. Polyspecificity scores for 138 clinical antibodies are shown for comparison (Jain et al., PNAS 1114(5), 944-949 (2017).

[0163] FIGS. 14A-14L contain a summary of the binding properties of SARS-CoV-2 S-specific antibodies based on the results from Examples 2 and 3. FIG. 14A shows apparent binding affinities of SARS-CoV-2 S-specific IgGs to recombinant prefiision-stabilized SARS-CoV-S and SARS-CoV-2-S proteins, as determined by BLI measurements. Antibodies for which binding curves could not be fit are designated as “p.f.” (meaning “poor fit”) on the plot. The majority of tested mAbs (153 out of 202) binds to both SARS-CoV-2-S and SARS-CoV-S, while a subset of mAbs are SARS-CoV-2 S- specific and that over half of the cross-reactive antibodies (89 / 153) bound with KDApp >10 nM to both SARS-CoV and SARS-CoV-2 S. FIG. 14B provides a heat map showing KDAPPSof the isolated antibodies for SARS-CoV, SARS-CoV-2, 229E, HKU1, NL63, and OC43 S proteins. Germline gene usage, clonal expansion, and SHM are indicated in the three leftmost panels. N.B., non-binder. FIG. 14C provides the load of somatic mutations in broadly cross-reactive (“Broad”) and SARS- CoV / SARS-CoV-2-specific (“SARS1 / 2 only”) antibodies. Black bars indicate medians. FIG. 14D provides the degree of clonal expansion in broadly cross-reactive (“Broad”) and SARS-CoV / SARS- CoV-2-specific (“SARS1 / 2 only”) antibodies. Each lineage is represented as a segment proportional to the lineage size. The total number of antibodies is shown in the center of the pie. FIG. 14E shows the proportion of broadly cross-reactive (“Broad”) and SARS-CoV / SARS-CoV-2-specific (“SARS1 / 2 only”) antibodies derived from IgG+and IgA+B cells, as determined by index sorting. FIG. 14F shows the load of somatic mutations in SARS-CoV-2 S-reactive antibodies isolated from three naive donors and VRC#202367. Antibodies from naive donors are pooled for this analysis. FIG. 14G compares the binding activity of SARS-CoV-2 S-reactive antibodies isolated from three naive donors and VRC#202367, as determined by BLI. The statistical significance (**) is between the data fromVRC#202367 and pooled data from three naive donors FIG. 14H shows VH / VL germline gene usage of SARS-CoV-2 S-specific antibodies that display cross-reactivity with circulating HCoV S proteins. FIGS. 141 and 14J show ELISA binding reactivity of healthy donor sera to SARS-CoV-2, SARS- CoV, and circulating HCoV S proteins. CR3022 is included as a positive control. FIG. 14K shows the percentage of SARS-CoV-2 S-specific B cells observed in each naive donor, as determined by flow cytometry. FIG. 14L shows the clonal lineage analysis. Each lineage is represented as a segment proportional to the lineage size. The total number of isolated antibodies is shown in the center of each pie. Clonal lineages were defined based on the following criteria: identical VH and VL germline gene, identical CDR H3 length, and CDR H3 amino acid identity >80%. Clonal lineages are not shown for Donor 1 because only three SARS-CoV-2 S-specific antibodies were isolated from this donor.

[0164] FIGS. 15A-15I show part of the results from the epitope mapping assays in Example 4. The KD[M], kon[M1s1], k0ff[s1], and Binding Response (nm) data for the SI subunit (monovalent or bivalent (“AVID”)) of the S protein of SARS-CoV-2, for each antibody are provided.

[0165] FIGS. 16A-16E show part of the results from the epitope mapping assays in Example 4. The KD[M], kon[M1s1], k0ff[s1], and Binding Response (nm) data for the S2 subunit of the S protein of SARS-CoV-2, for each antibody are provided.

[0166] FIGS. 17A-17I show part of the results from the epitope mapping assays in Example 4. The KD[M], kon[M1s-1], k0ff[s1], and Binding Response (nm) data for the RBD domain (monovalent or bivalent (“AVID”) of the S protein of SARS-CoV-2, for each antibody are provided.

[0167] FIGS. 18A-18E show some of the results from the epitope mapping assays in Example 4. The KD[M], kon[M1s1], k0ff[s1], and Binding Response (nm) data for the N-terminal domain (NTD) of the S protein of SARS-CoV-2, for each antibody are provided.

[0168] FIGS. 19A-19I provide a summary of the binding affinity results from FIGS. 15-18. In these figures, when an antibody showed a binding response (nm) value of 0.1 or higher for a target, the antibody was considered as a binder (shown as “Yes”) to that target. Note that for antibodies with a binding response value such as 0.099 or 0.098 that can be round up to 0.1; these antibodies were also identified as binders and shown as “Yes”. By contrast, when an antibody showed a binding response (nm) value of < 0.1 for a target in FIGS. 15-18, the antibody was considered as a non-binder (shown as “No”) for that target.

[0169] FIGS. 20A-20F provide the results from the cell binding assays in Example 5. FIGS. 20A- 20E show binding of each antibody to cells engineered to express the S protein of SARS-CoV-2 on the surface is shown in fold binding over background and in EC50 [nM] FIG. 20F shows binding of SARS-CoV-2 S-specific antibodies to SARS-CoV S expressed on the surface of cells. As shown therein none of the antibodies tested showed significant binding to recombinant prefusion-stabilized SARS-CoV S, as determined by BLI. In these binding assays antibodies were tested at a 100 nM concentration.

[0170] FIGS. 21A-21E show the results from the binding competition assays in Example 4. The figures show whether the binding of each tested antibody competed with ACE2 or a commercially available antibody, CR3022.

[0171] FIG. 21F is a summary of results shown in FIGS. 15-18 and 21. The chart provides the proportion of different antigenic sites within SARS-CoV-2-S of the 65 tested antibodies that bind to SARS-CoV-2-S with KDApps<10 nM. The different antigenic sites are the S2 subunit, the NTD within the SI subunit, and the RBD within the SI subunit. As shown therein of the antibodies that bound to the RBD, only some competed with hACE2. Those which did not compete with hACE2 are also shown.

[0172] FIGS. 22A-22I show the results from the neutralization assays in Example 6.

[0173] FIGS. 23A-23E contain analyses of the relationship between the binding epitope and the neutralizability of the antibodies. FIG. 23A provides a graph showing percent authentic SARS-CoV-2 infection observed in the presence of each antibody identified by “Antibody index” (x axis) at a concentration of 100 nM. The corresponding antibody names are shown in Table 5 below. Bars are colored by targeted antigenic site. FIG. 23B provides a graph showing the % neutralization of authentic SARS-CoV-2 virus of each antibody (y axis) by the epitope / antigenic site within SARS- CoV-2-S (x axis). For RBD-binding antibodies, the target is further specified by whether the antibody competes with hACE2. FIG. 23C provides a heat map showing the neutralizing activities and competitive binding profiles of the RBD-directed antibodies. FIG. 23D provides neutralization of authentic SARS-CoV-2 (strain n-CoV / USA_WAl / 2020) by antibodies as measured by a micro neutralization assay on Vero E6 cells. The negative control antibody, ADI-26140, is specific for chicken egg lysozyme. CR3022 is included for comparison. FIG. 23E provides a dot plot showing binding to cell-surface SARS-CoV-2 S (shown in FOB on y axis) versus SARS-CoV-2 neutralization at a 100 nM concentration (shown in % on x axis). Each point represents a single antibody and data points are colored by the antigenic site. In the figure “FOB” refers to fold over background.

[0174] FIGS. 23F-23G show the results from the neutralization assays on selected antibodies in Example 6. FIG. 23F provides neutralization of SARS-CoV and SARS-CoV-2 MLV pseudovirus (strain n-CoV / USA_WAl / 2020) by eight antibodies using HeLa-ACE2 target cells. FIG. 23G provides neutralization of authentic SARS-CoV and SARS-CoV-2 using Vero E6 target cells. Data represents two technical replicates. Antibodies with black arrow were selected for affinity maturation in Example 12.

[0175] FIG. 24 provides graphs showing correlation between authentic SARS-CoV-2 neutralization IC50 using Vero E6 target cells and (top) MLV-SARS-CoV-2 pseudovirus neutralization IC50 using HeLa-ACE2 target cells or (bottom) VSV-SARS-CoV-2 neutralization IC50 using Vero E6 target cells. R2 values were calculated using linear regression.

[0176] FIG. 25 provides a summary of neutralization IC50 [ug / mL] values for neutralization assays using nine selected antibodies and different viruses as shown therein.

[0177] FIG. 26 provides a summary of authentic SARS-CoV-2 neutralization IC50 [ug / mL] values and of affinities (KDvalues) to SARS-CoV-S and SARS-CoV-2-S, for seven selected antibodies. Based on their binding properties some of these antibodies were selected for further affinity maturation.

[0178] FIGS. 27A-27C provide clusters based on the VH CDR3 sequences among selected antibodies, as tested in Example 7.

[0179] FIGS. 28A-28B provide sample plots for the clusters containing more than 2 antibodies, i. e. , Clusters 1 through 5.

[0180] FIG. 29 provides the amino acid changes introduced by affinity maturation in Example 12. Amino acid changes for ADI-57983, ADI-57978, and ADI-56868 are relative to the sequence the parent (i.e., before affinity maturation in Example 12) antibody, ADI-55689, ADI-55688, and ADI- 56046, respectively.

[0181] FIG. 30A provides a graph comparing affinity to SARS-CoV-2-S of parent antibodies (i.e. , before affinity maturation in Example 12) and affinity maturation progenies (after one or two cycles), measured in Example 13.

[0182] FIG. 30B provides a graph comparing parent antibodies (i.e., before affinity maturation in Example 12) and affinity maturation progenies for the ability to neutralize authentic SARS-CoV-S and SARS-CoV-2, measured in Example 14. Data points corresponding to the lead progeny derived from ADI-55689 are marked “ADI-57983”.

[0183] FIG. 30C provides representative yeast surface display library selections. Four flow cytometry panels on the left show flow cytometric sorting of yeast display libraries containing diversity in the ADI-55688 HC (top) or LC (bottom). Libraries were sorted for improved binding to the SARS-CoV-2 SI protein relative to the parent clone. Round 1 gates indicate the yeast populations that were sorted for a second round of selection, and round 2 gates indicate the yeast populations that were sorted for amplification of heavy- or light-chain variable region genes and transformation into yeast for HC / LC combinatorial library generation. Two flow cytometry panels on the right shown flow cytometric sorting of HC / LC combinatorial libraries. Libraries were sorted for improved binding to the SARS-CoV-2 SI protein relative to the round 2 output of the HC diversity libraries. The round 1 gate indicates the yeast population that was sorted for a second round of selection and the round 2 gate indicates the yeast population that was sorted for individual colony picking. The scheme illustrates the combined heavy chain and light chain selection for affinity maturation in Example 12,

[0184] FIG. 30D provides flow cytometry plots from the terminal round of selection showing binding of parental antibodies and affinity maturation libraries to the SARS-CoV-2 SI protein at a 1nM concentration. Gates indicate the yeast populations sorted for antibody sequencing and characterization.

[0185] FIG. 31A provides summary information regarding the origin (donor, B cell phenotype, and, if applicable, lineage (i.e.. the antibody before affinity maturation induced in Example 12)). epitope within the S protein of SARS-CoV-2, and neutralization IC50 values for five selected antibodies.

[0186] FIG. 31B provides a summary of antibody developability parameters measured in Example 18 for five selected antibodies “pi”, isoelectric point; “PSR”, interaction with polyspecificity reagent; “HIC”, Hydrophobic interaction chromatography; “Tm”, melting temperature.

[0187] FIGs. 32A-32H provide the results from Examples 16 and 19, the binding kinetics of two antibodies isolated from convalescent COVID-19 patients in Example 15. The binding specificity summary (FIG. 32A) and individual binding parameters for SARS-CoV-2-S (FIG. 32B), for the RBD of SARS-CoV-2-S (FIG. 32C), for the NTD of SARS-CoV-2- S (FIG. 32D), for SI subunit of SARS- CoV-2-S (FIG. 32E), for S2 subunit of SARS-CoV-2-S (FIG. 32F), and for the seasonal CoV HKU 1 S protein (FIG. 32G), and competition assay results (FIG. 32H) are provided.

[0188] FIGs. 32I-32J provide the results from the cross-competition study in Example 20 for selected antibodies.

[0189] FIG. 33 provide the results from neutralization assays in Example 17 on two antibodies isolated from convalescent COVID-19 patients.

[0190] FIG. 34 provides the amino acid changes made in the five antibodies (ADI-58120, ADI- 58124, ADI-58126, ADI-58128, and ADI-58130) to fix the mutation(s) away from the germline- encoded sequence caused by the degenerate primers to match the germline-encoded sequence.

[0191] FIG. 35 provides the germline origin of the VH and VL and the number of amino acid or nucleotide substitutions relative to the germline-encoded or greyline sequence, respectively, in the VH and VL of ADI-58120, ADI-58124, ADI-58126, ADI-58128, and ADI-58130 (antibodies after the fixation of “primer mutation” back to the germline sequence as described in FIG. 34).

[0192] FIG. 36A provides the SEQ ID NOs assigned to the respective VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VH CDR3, and VH FR4 amino acid sequences, the respective VH amino acid sequences, the respective heavy chain amino acid sequences, and the respective VH-endcoding DNA sequences for different antibodies.

[0193] FIG. 36B provides the SEQ ID NOs assigned to the respective VL FR1, VL CDR1, VL FR2, VL CDR2, VL FR3, VL CDR3, and VL FR4 amino acid sequences, the respective VL amino acid sequences, and the respective light chain amino acid sequences, and the respective VL-endcoding DNA sequences for different antibodies.

[0194] FIG. 37A provides exemplary binding kinetics of pre-affinity maturation antibodies (ADI- 55689, ADI-55688, and ADI-56046) and post-affinity maturation antibodies derived therefrom, respectively, after fixing primer mutations (ADI-58120, ADI-58124, and ADI-58126). The SPRsensorgrams show binding of each Fab to SARS-CoV-2 RBD-SD1. Binding data are shown as black lines and the best fit of a 1 : 1 binding model is shown as red lines.

[0195] FIG. 37B provides a comparison of the affinity to SARS-CoV-2 S protein of ADI-58124 and its parental antibodies, which are antibodies used to obtain ADI-58124 by affinity maturation (i.e.. ADI-55688) and cycle 1 and cycle 2 affinity maturation progenies.

[0196] FIG. 37C provides a table summarizing binding kinetics of ADI-58125 as a full IgG or a Fab to SARS-CoV-2 S protein, SARS-CoV-2 RBD, SARS-CoV S protein, SARS-CoV RBD, or WIV-1 RBD.

[0197] FIGS. 38A-38D compare biophysical properties of antibodies according to the present disclosure, anti-SARS-CoV-2 antibodies currently under clinical trials, and 42 clinically approved antibodies (Jain T. et al, Proc Natl Acad Sci U SA. 2017 Jan 31;114(5):944-949). FIG. 38A compares polyreactivity scores, as determined as described previously (L. Shehata et al, Cell Reports 28, 3300-3308 e3304 (2019)). The thresholds for high, low, and clean polyreactivity were defined based on a previously reported correlation between polyreactivity score and serum half-life in humans (L. Shehata et al, Cell Reports 28, 3300-3308 e3304 (2019)). FIG. 38B compares hydrophobicity, as determined by hydrophobic interaction chromatography. FIG. 38C compares self-interaction propensity (left), as determined by affinity-capture self-interaction nanoparticle spectroscopy (Liu Y. et al,MAbs. Mar-Apr 2014;6(2):483-92.). FIG. 38D compares thermal stability (right) defined by Fab melting temperatures, as determined by differential scanning fluorimetry (DSF).

[0198] FIGS. 39A-39F compares neutralization of different coronaviruses and pseudoviruses by ADI-58124 and its parent ADI-55688, and anti-SARS-CoV-2 antibodies currently under clinical trials. FIG. 39A provides a dot plot showing MLV-SARS-CoV-2 pseudovirus neutralization IC50s of parental antibodies and affinity matured progenies. FIG. 39B provides a heat map (top) and a graph (bottom) showing the neutralization IC50s of the indicated antibodies against authentic SARS-CoV, WIV-l-nluc, SHC014-nluc, SARS-CoV -2 -nluc, and SARS-CoV-2 using either HeLa-ACE2 or Vero target cells. SARS-CoV, WIV-l-nluc, SHC014-nluc, and SARS-CoV-2 nluc assays were run using Vero target cells. WIV-l-nluc, SHC014-nluc, and SARS-CoV-2-nluc are recombinant, reverse- genetics-derived viruses encoding a nano-luciferase reporter gene. FIGS. 39C and 39D provide individual neutralization curves of pre- and post-affinity maturation antibodies and clinical antibodies against authentic SARS-CoV, WIVl-nLuc, SHC014-nLuc, and mouse adapted SARS-CoV-2-MA2- nLuc (“SARS2-nLuc”) viruses on Vero E6 cells. FIG. 39E provides authentic SARS-CoV-2 neutralization titrations with ADI-58124, performed using either HeLa-ACE2 (left) or Vero (right) target cells. The curves were fitted by nonlinear regression (log [inhibitor] vs. normalized response, variable slope). IC50 values for ADI-58125 and ADI-58129, along with clinical antibodies are also provided. FIG. 39F shows exemplary neutralizing activity by ADI-58124 against WA1 strain ofSARS-CoV-2, WT or D614G, measured using an MLV-based pseudovirus assay in HeLa-ACE2 target cells.

[0199] FIGS. 39G-39M provide exemplary neutralization data obtained with antibodies according to the present disclosure having a wild-type or non-wild type Fc and with anti-SARS CoV-2 antibodies under clinical trials. FIG. 39G shows neutralization of authentic SARS-CoV-2 by ADI-58125 assayed using ELISA in HeLa-ACE2 cells (top) and VeroE6 cells (bottom). FIG. 39H shows neutralization of SHC014 (top left) and WIV1 (top right) SARS-like coronaviruses from bats (both encoding luciferase reporter) by ADI-58125 assayed using the luciferase assay system in VeroE6 cells. IC50 and IC90 values for ADI-58125 and IC50 values for other antibodies are also provided. FIG. 391 shows neutralization of SARS-CoV pseudotype MLV virus (left), SARS-CoV-2 pseudotype MLV virus (center), or SARS-CoV-2 D614G pseudotype MLV virus (right) (all encoding luciferase reporter) by ADI-58125 assayed using the luciferase assay system in HeLa-ACE2 cells. IC50 and IC90 values for ADI-58125 and IC50 values for ADI-58129 and clinical antibodies are also provided. FIG. 39J shows exemplary inhibition of authentic SARS-CoV infection by indicated antibodies assayed using the method described herein in Vero E6 cells. IC50 values are also provided. FIGS. 39K-39M provide exemplary neutralizing activity by indicated antibodies against SARS-CoV pseudotype MLV virus (top left), SARS-CoV-2 pseudotype MLV virus (top right), and SARS CoV-2 D614G mutant pseudotype MLV virus (bottom), respectively, assayed using the luciferase assay system in HeLa-ACE2 cells.

[0200] FIG. 39N provides authentic SARS-CoV-2 neutralization titrations with ADI-58125 performed using either HeLa-ACE2 (top) or Vero (bottom) target cells. The curves were fitted by nonlinear regression (log [inhibitor] vs. normalized response, variable slope).

[0201] FIG. 390 provides a comparison of IC50 values (top) and neutralization plateau (bottom) for ADI-58125 and ADI-58129, along with clinical antibodies.

[0202] FIGS. 40A-40J compares the breadth of binding to diverse sarbecoviruses and circulating SARS-CoV-2 variants by ADI-58120, ADI-58124, ADI-58125, and ADI-58126, and anti-SARS- CoV-2 antibodies in clinical trials. ADI-58125 and ADI-58124 share the same CDR sequences and only differ in the Fc region which has been engineered for half-life extension purpose. FIG. 40A provides a phylogenetic tree of 57 sarbecoviruses constructed from mafft and maximum likelihood analysis of RBD-SDl amino acid sequences extracted from the European Nucleotide Archive and GISAID database. Representative sarbecovirus RBDs included for further study are in bold text and colored according to their canonical phylogenetic lineages. FIG. 40B provides a heat map of apparent equilibrium dissociation constants (KDApp) against 17 representative yeast-displayed RBDs, determined by normalized nonlinear regression fitting. FIG. 40C provides binding to yeast-displayed RBD of naturally -occurring SARS-CoV-2 variants. Briefly, SARS-CoV-2 sequences were retrieved from the GISAID database on July 14, 2020 (n = 63551). Mutants observed more than 6 times andpublished antibody escape mutants also observed in the database were chosen for analysis. Binding signal was normalized to RBD expression and calculated as percent antibody binding to the variant SARS-CoV-2 RBD relative to the WT SARS-CoV-2 RBD, assessed at their respective KDAPPconcentrations for the WT RBD construct. The prevalence of each variant, calculated from deposited sequences on October 19, 2020 (n = 148115), is shown as a percentage of the total number of sequences analyzed. FIG. 40D provides a graph showing association between the number of natural SARS-CoV-2 variants with observed loss of binding, defined as less than 25% of WT SARS-CoV-2 binding, and percentage of Clade I sarbecovirus RBDs recognized by individual antibodies. FIG. 40E provides a heat map of apparent equilibrium dissociation constants (KDApp) against 17 representative yeast-displayed RBDs, determined by normalized nonlinear regression fitting. KD (nM) values for ADI-58120, ADI-58125, ADI-58126, and clinical antibodies are also provided. FIG. 40F provides binding of ADI-58124 to yeast-displayed RBD of naturally occurring SARS-CoV-2 variants. FIG. 40G provides a comparison between binding of ADI-58125 to yeast-displayed RBD of naturally occurring SARS-CoV-2 variants with other clinical antibodies. FIG. 40H depicts that ADI-58125 binds with comparable affinity to all common circulating SARS-CoV-2 variants and emerging lineages B.1.1.7 / 501Y.V1 (UK), B.1.351 / 501Y.V2 (South African) and P.1 / 501Y.V3 (Brazilian).FIG. 401 depicts that neutralization of P.I., Vctoria, B.1.17 and B.1351 strains by a panel of human monoclonal antibodies. ADI-58122, ADI-58125 and ADI-58127 retained high affinity binding to P.1 varaint with all reaching a plateau at 100% neutralization.

[0203] FIG. 40 J depicts antibody mediated inhibition of SARS-CoV-2 spike (S) protein binding to human ACE2. S binding to ACE2-coated plates was assessed in the presence of varying concentration of selected antibodies in an ELISA assay.

[0204] FIGS. 41A-41G demonstrate that ADI-58120, ADI-58124, ADI-58126, and ADI-58128 respectively bind to a conserved epitope on the SARS-CoV-2 RBD overlapping with the hACE2 binding site. FIG. 41A provides a schematic showing the generation and selection of a mutagenized, yeast surface-displayed SARS-CoV-2 RBD library to identify mutations that prevent ADI-58124 binding. FIG. 41B provides exemplary titration curves of indicated antibodies and hACE2 for binding to yeast surface displayed WT SARS-CoV-2 RBD. FIG. 41C provides exemplary flow cytometric selections of clones from mutagenized SARS-CoV-2 RBD library with diminished ADI-58124 binding relative to WT SARS-CoV-2 RBD. FIG. 41D provides a graph showing binding to RBD clones with single amino acid substitutions by indicated antibodies and hACE2 relative to WT RBD. FIG. 41E provides a heat map showing all of the RBD mutations identified from yeast surface display selections that specifically abrogate binding of ADI-58120, ADI-58124, ADI-58125, ADI-58126, ADI-58128, CR3022, REGN10933, REGN10987, JS016, S309, and / or hACE2. Values indicate percent antibody or hACE2 binding to the mutant SARS-CoV-2 RBD relative to the WT SARS-CoV- 2 RBD, assessed at their respective ECso concentrations for the WT RBD construct. FIG. 41Fprovides a heat map essentially same as the heat map in FIG. 41H but only showing RBD mutations that specifically abrogate binding of ADI-58120, ADI-58124, ADI-58125, ADI-58126, and / or ADI- 58128 (top) or of ADI-58124 (bottom). FIG. 41G provides a protein sequence alignment of representative sarbecovirus RBDs with sequences colored by percentage sequence identity and conservation shown as a bar plot. Positions delineating the receptor binding motif are based on the SARS-CoV-2 RBD and residues determined to be important for ADI-58124 binding based on fine epitope mapping data shown in FIG. 41D are denoted by star.

[0205] FIGS. 41H-41 J provide results from the escape mutant analyses in Example 27. The ability of ADI-58120 (FIG. 41H (left)), ADI-58124 (FIG. 41H (right)), ADI-58126 (FIG. 411 (left)), ADI- 58128 (FIG. 411 (right)), and ADI-58130 (FIG. 41J) to inhibit infection of Vero cells by rVSV comprising indicated SARS-CoV-2 S protein mutants was tested. Increased IC50 indicates that the indicated mutation in the S protein conferred resistance.

[0206] FIGS. 42A-42H provide results from the competitive binding analyses in Example 28. FIGS. 42A-42B provide exemplary bio-layer interferometry (BLI) sensograms showing competition between respective antibodies with ACE2 in binding to SARS-CoV-2 S protein. ADI-26140 was used as a negative control. A rise in amplitude in the second step (to the right of the vertical line in the sensorgram) indicates an available binding site for ACE2 binding. FIGS. 42C-42G provide BLI graphs of SARS-CoV-2 S trimer in solution loading onto an anti-heavy chain probe preloaded with respective 1stantibodies, followed by loading with respective second antibodies in solution, demonstrating competitive or non-competitive binding between the 1stand 2ndantibodies. A rise in amplitude in the second step indicates no competition between the 1stand 2ndantibodies, and no rise in amplitude in the second step indicates competition between the 1stand 2ndantibodies. FIG. 42H provides a summary of competition between indicated antibodies, or between an indicated antibody and hACE2, based on the competitive binding analyses in Example 28.

[0207] FIGS. 43A-43C provide binding of ADI-58124 and ADI-58125 to different Fc gamma receptors (FIG. 43A), human or cynomolgus FcRn (FIG. 43B), and human Clq (FIG. 43C). FIG. 43C depicts that Fc engineering of ADI-58124 resulted in ADI-58125 with improved binding to human and cynomolgus FcRn at low pH. In particular, the expected half-life in humans for ADI- 58124 was about 20-25 days, while the expected half-life for ADI-58125 in humans is about 70-115 days.

[0208] FIGS. 43D-43E demonstrates that ADI-58124 and ADI-58125 trigger Fc-mediated effector functions. The indicated antibodies were assessed for the ability to induce Fc-mediated effector functions against RBD-coated targets at varying concentrations. In FIG. 43E, primary human NK cells were analyzed for surface expression of CD 107a, indicating degranulation (top left), and the production of IENg (top center) or TNFa (top right) following incubation with antibody-RBD immune complexes for 5 hours. Antibody-mediated phagocytosis of RBD-coated fluorescent beads bydifferentiated HL-60 neutrophils (bottom left) or THP-1 monocytes (bottom center) was measured following incubation with immune complexes for 18 hours. Antibody-mediated complement deposition was measured by detection of complement component C3 onto RBD-coated fluorescent beads following incubation of guinea pig complement with immune complexes for 20 minutes (bottom right). In FIG. 43E, the area under the curve (AUC) in the three graphs (ADCD, ADCP, and ADNKA CD 107a) shown in FIG. 43D was calculated as the sum of the products of response x concentration using GraphPad Prism.

[0209] FIG. 43F provides comparison of ADI-58124 and ADI-58125 in the ability to induce ADCC. In the top panel, SARS-CoV-2 S-coated plates were used to evaluate ADI-58124 and ADI-58125 and negative control antibody to assess CD16A activation of Jurkat-Luria cells. The lower dotted line represents the baseline signal of cells and media online (no antibody). The upper dotted line represents positive control signal from a cell stimulation cocktail plus ionomycin. In the bottom panel, SARS-CoV2 RBD-coated plates used in the ADCC assay.

[0210] FIGS. 44A-44D demonstrate that ADI-58125 protects mice from SARS-CoV- and SARS- CoV-2-associated viral diseases, as evaluated in Example 30. FIG. 44A and FIG. 44B show efficacy of prophylactic treatment with ADI-58125 in SARS-CoV-MA15 and SARS-CoV-2-MA10 challenge models, respectively. A single dose of ADI-58125 or sham treatment were delivered intraperitoneally 12 hours prior to infection. Mouse body weight and respiratory function were monitored for 4 days. Gross lung hemorrhage scores were determined on day 2 (MAI 5) or day 4 (MAIO) post-infection and lung viral titers were measured on day 2 and day 4 post-infection. FIG. 44C provides effects by therapeutic treatment with ADI-58125 or sham treatment at 12 hours post-SARS-CoV-2-MA15- infection. Mouse body weight, respiratory function, gross hemorrhage scores (day 2), and lung viral titers (days 2 and 4) were assessed as described above. Statistical comparisons were made using Mann-Whitney U tests or two-sided t-tests with Holm-Sidak corrections for multiple comparisons (*P < 0.05, **P < 0.01; ***P < 0.001). Dotted lines indicate the limit of detection. FIG. 44D shows exemplary neutralizing activity by ADI-58124 against SARS-CoV-MA (“SARSlMA”)-nLuc or WT or mouse adapted SARS-CoV-2 (“SARS2”), the virus used in the in vivo study. In the top panel, mean and SEM of the luciferase signal are expressed as percentage inhibition or neutralization for ADI- 58125 and SARS-CoV MA-nLuc. In the bottom panel, mean and SEM of the luciferase signal are expressed as percentage inhibition or neutralization for ADI-58125 and SARS-CoV-2 MA-nLuc. A table showing IC50s for ADI-58125 in the neutralization curves for SARS1 -MA-nLuc and SARS2- MA2-nLuc is also provided.

[0211] FIGS. 45A-45B provide results from the studies on potential antibody-dependent enhancement (ADE) in Example 31. Luciferase-labeled reporter viral particles were culture with phagocytes, THP-1 cells (FIG. 45A) or Raji cells (FIG. 45B), in the presence of variedconcentrations of respective test antibodies. Increase in the luciferase signal indicates uptake of viral particles by phagocytes.

[0212] FIG. 45C provide results from the studies on potential antibody-dependent enhancement (ADE) for ADI-58124 and ADI-58125.

[0213] FIG. 46 depicts the serum concentration of ADI-58125 and the predicted serum neutralizing titers following a single 300 mg intramuscular (IM) dose.

[0214] FIG. 47A depicts the serum concentration of ADI-58125 and the upper and lower respiratory ELF concentrations following a single dose of 600 mg IM.

[0215] FIG. 47B depicts the serum concentration of ADI-58125 and the upper and lower respiratory ELF concentrations following a single 1200 mg intravenous (IV) dose over 1 hour.

[0216] FIG. 47C depicts the serum concentration of LY-CoV555 and the upper and lower respiratory ELF concentrations following a single dose of 700 mg IV over 1 hour.

[0217] FIG. 47D depicts the serum concentration of REGN10987 and the upper and lower respiratory ELF concentrations following a single dose of 1200 mg IV over 1 hour.

[0218] FIG. 48A depicts the viral load following a single dose of 600 mg IM ADI-58125 and 2400 mg IV REGN-COV2.

[0219] FIG. 48B depicts the viral load following a single dose of 1200 mg IV ADI-58125 and 2400 mg IV REGN-COV2.

[0220] FIG. 48C depicts the viral load change relative to REGN-COV2 following a single dose of 600 mg IM ADI-58125 and 2400 mg IV REGN-COV2.

[0221] FIG. 48D depicts the viral load change relative to REGN-COV2 following a single dose of 1200 mg IV ADI-58125 and 2400 mg IV REGN-COV2.

[0222] FIG. 49A depicts the mean serum concentration of ADI-58125 after IV fusion and IM administration to male and female cynomolgus monkeys. FIG. 49B depicts the pharmacokinetic parameters of ADI-58125 in male and female Cynomolgus monkeys.

[0223] FIGS. 50A-50C depict that ADI-58122 and ADI-58125 potently neutralize UK (B.1.1.7), South African (B.1.351) and / or Brazilian (P.l) SARS-CoV-2 variants. FIG. 50A shows the IC50 values for selected antibodies against the indicated SARS-CoV-2 variants. FIG. 50B depicts the maximal neutralization level for ADI-58122, ADI-58125, REGN10987 and S309 against the indicated SARS-CoV-2 variants. FIG. 50C depicts the maximal neutralization level for selected antibodies against the indicated SARS-CoV-2 variants.

[0224] FIG. 51 depicts that neutralization IC50 for selected antibodies against the Victoria, UK (B.l.1.7) and South African (B.1.351) SARS-CoV-2 variants.

[0225] FIG. 52A depicts that ADI-58125 retains high binding affinity to the RBDs of the B.1.1.7 (UK), B.1.351 (South African) and B.1.1.128 (Brazilian) variants. FIG. 52B depicts that ADI-58125retains high binding affinity to the RBDs of the B.l.1.7 (UK), B.1.351 (South African), B.1.1.128 (Brazilian) and B.1.429 (southern California) variants.

[0226] FIG. 53A is a schematic representation for the in vivo efficacy study in hamsters. Hamsters were treated with a range of ADI-58125 doses (9.25 - 2000 pg) or control mAb 24 hours prior to challenge with SARS-2 / WA-1 to evaluate prophylactic efficacy of ADI-58125.

[0227] FIGS. 53B and 53C depict the prophylactic efficacy of ADI-58125 in the Syrian hamster model of SARS-CoV-2 infection as assessed by viral load (plaque assay, genomic RT-PCR, subgenomic RT-PCR), body weight, and histopathology. FIG. 53B depicts the SARS-CoV-2 lung viral loads on Days 3 and 6 (by plaque assay), and FIG. 53C depicts the changes from baseline in weight on Day 6.

[0228] FIG. 54A is a schematic representation for the in vivo efficacy study in non-human primates (NHP). Rhesus macaques were treated with ADI-58125 at 5 mg / kg or 25 mg / kg, or control mAb (25 mg / kg) 3 days prior to challenge with SARS-2 / WA-1 to evaluate prophylactic efficacy of ADI-58125.

[0229] FIG. 54B depicts the prophylactic efficacy of ADI-58125 in the NHP model of SARS-CoV-2 infection: impact on genomic (left panels) and sub-genomic (right panels) viral RNA in NP and BAL samples. BAL, bronehoalveolar lavage; NP, nasopharyngeal; RT-PCR, reverse transcription- polymerase chain reaction.DETAILED DESCRIPTIONA. Definitions

[0230] It is to be understood that this disclosure is not limited to the particular methodology, protocols, cell lines, animal species or genera, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present disclosure, which will be limited only by the appended claims. As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the protein" includes reference to one or more proteins and equivalents thereof known to those skilled in the art, and so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs unless clearly indicated otherwise.

[0231] Spike protein (S protein ): As used herein, unless stated otherwise S protein includes any coronavirus form of S protein. The term coronavirus S protein (“CoV-S”) is used to describe the S protein of any coronaviruses. In particular, the “SARS-CoV-S” and “SARS-CoV-2-S” encompass the S protein of SARS-CoV and of SARS-CoV-2. SEQ ID NO: 1 is an exemplary polypeptide sequence of SARS-CoV-S, comprising 1288 amino acids (Accession# PDB: 6VSB B). SEQ ID NO: 5 is an exemplary polypeptide sequence of SARS-CoV-2-S, comprising 1273 amino acids (GenBank:QHD43416.1). SEQ ID NO: 2 (3864 nucleotides) encodes the SARS-CoV-S (SEQ ID NO: 1) and SEQ ID NO: 6 (3822 nucleotides, NC_045512:21563.25384, also see the corresponding region of GenBank: MN908947) encodes SARS-CoV-2-S (SEQ ID NO: 5).

[0232] In some embodiments, the “SARS-CoV-S” and “SARS-CoV-2-S” encompass any mutants, splice variants, isoforms, orthologs, homologs, and variants of SEQ ID Nos 1 and 5. In some embodiments, the CoV-S comprises a polypeptide sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to either SEQ ID NO: 1 or SEQ ID NO:5.

[0233] “Effective treatment or prevention of CoV infection” herein refers to eliminating CoV from the subject or preventing the expansion of CoV in the subject or eliminating or reducing the symptoms such as fever, cough, shortness of breath, runny nose, congestion, conjunctivitis, and / or gastrointestinal symptoms after administration of an effective amount of an anti-CoV-S antibody or antigen-binding fragment thereof. In some instances, effective treatment may eliminate the need for the subject to be placed on a ventilator or reduce the time the subject needs to be on a ventilator. The treatment may be effected as a monotherapy or in association with another active agent such as an antiviral agent or anti-inflammatory agent by way of example.

[0234] As used herein, "treatment" is an approach for obtaining beneficial or desired clinical results. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, one or more of the following: improvement in any aspect of COV-S-related conditions such as fever or cough. For example, in the context of CoV infection treatment this includes lessening severity, alleviation of fever, cough, shortness of breath, and other associated symptoms, reducing frequency of recurrence, increasing the quality of life of those suffering from the CoV-related symptoms, and decreasing dose of other medications required to treat the CoV-related symptoms. Other associated symptoms include, but are not limited to, diarrhea, conjunctivitis, loss of smell, and loss of taste. Still other symptoms which may be alleviated or prevented include inflammation, cytokine storm and / or sepsis.

[0235] "Reducing incidence" or “prophylaxis” or “prevention” means any of reducing severity for a particular disease, condition, symptom, or disorder (the terms disease, condition, and disorder are used interchangeably throughout the application). Reduction in severity includes reducing drugs and / or therapies generally used for the condition by, for example, reducing the need for, amount of, and / or exposure to drugs or therapies. Reduction in severity also includes reducing the duration, and / or frequency of the particular condition, symptom, or disorder (including, for example, delaying or increasing time to next episodic attack in an individual). This further includes eliminating the need for the subject to be placed on a ventilator or reducing the time the subject needs to be on a ventilator.

[0236] "Ameliorating" one or more symptoms of CoV infection-related conditions means a lessening or improvement of one or more symptoms of the condition, e.g., fever or cough or shortness of breath as compared to not administering an anti-CoV-S antagonist antibody. "Ameliorating" also includesshortening or reduction in duration of a symptom. Again, this may include eliminating the need for the subject to be placed on a ventilator or reducing the time the subject needs to be on a ventilator.

[0237] As used herein, "controlling CoV-related symptom” or “controlling” another CoV-S-related condition refers to maintaining or reducing severity or duration of one or more symptoms of the condition (as compared to the level before treatment). For example, the duration or severity or frequency of symptoms is reduced by at least about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% in the individual as compared to the level before treatment. The reduction in the duration or severity, or frequency of symptoms can last for any length of time, e.g., 2 weeks, 4 weeks (1 month), 8 weeks (2 months), 16 weeks (3 months), 4 months, 5 months, 6 months, 9 months, 12 months, etc.

[0238] As used therein, "delaying" the development of a CoV-S-related condition such as shortness of breath, bronchitis, or pneumonia e.g., interstitial), means to defer, hinder, slow, retard, stabilize, and / or postpone progression of the condition or disease. This delay can be of varying lengths of time, depending on the history of the condition or disease and / or individuals being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop symptoms. A method that "delays" development of the symptom is a method that reduces probability of developing the symptom in a given time frame and / or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects.

[0239] "Development" or "progression" of a CoV-related condition such as cough or fever means initial manifestations and / or ensuing progression of the disorder. Development of cough or fever can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development, or progression refers to the biological course of the symptoms. "Development" includes occurrence, recurrence, and onset. As used herein "onset" or "occurrence" of a condition includes initial onset and / or recurrence.

[0240] As used herein, an "effective dosage" or "effective amount" of drug, compound, or pharmaceutical composition is an amount sufficient to effect beneficial or desired results. For prophylactic use, beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity, or delaying the outset of the disease, including biochemical, histological, and / or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include clinical results such as reducing symptom intensity, duration, or frequency, and decreasing one or more symptoms resulting from CoV infection, including its complications and intermediate pathological phenotypes presenting during development of the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required totreat the disease, enhancing effect of another medication, and / or delaying the progression of the disease of patients, eliminating the need for the subject to be placed on a ventilator or reducing the time the subject needs to be on a ventilator.

[0241] An effective dosage can be administered in one or more administrations. For purposes of this disclosure, an effective dosage of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective dosage of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an "effective dosage" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.

[0242] A “suitable host cell” or “host cell” generally includes any cell wherein the subject anti-CoV- S antibodies and antigen-binding fragments thereof can be produced recombinantly using techniques and materials readily available. For example, the anti-CoV-S antibodies and antigen-binding fragments thereof of the present disclosure can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells (e.g., yeast), and cultured higher eukaryotic cells (including cultured cells of multicellular organisms), particularly cultured mammalian cells, e.g., human or non-human mammalian cells. In an exemplary embodiment these antibodies may be expressed in CHO cells. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al. , Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press (1989), and Current Protocols in Molecular Biology, Ausubel et al, editors, New York, NY : Green and Wiley and Sons (1993).

[0243] In some exemplary embodiments the antibodies may be expressed in mating competent yeast, e.g., any haploid, diploid ortetraploid yeast that can be grown in culture. Yeast useful in fermentation expression methods may exist in a haploid, diploid, or other polyploid form.

[0244] A “selectable marker” herein refers to a gene or gene fragment that confers a growth phenotype (physical growth characteristic) on a cell receiving that gene as, for example through a transformation event. The selectable marker allows that cell to survive and grow in a selective growth medium under conditions in which cells that do not receive that selectable marker gene cannot grow. Selectable marker genes generally fall into several types, including positive selectable marker genes such as a gene that confers on a cell resistance to an antibiotic or other drug, temperature when two temperature sensitive (“ts”) mutants are crossed or a ts mutant is transformed; negative selectable marker genes such as a biosynthetic gene that confers on a cell the ability to grow in a mediumwithout a specific nutrient needed by all cells that do not have that biosynthetic gene, or a mutagenized biosynthetic gene that confers on a cell inability to grow by cells that do not have the wild type gene; and the like.

[0245] An “expression vector” herein refers to DNA vectors containing elements that facilitate manipulation for the expression of a foreign protein within the target host cell, e.g., a bacterial, insect, yeast, plant, amphibian, reptile, avian, or mammalian cell, e.g., a CHO or HEK cell. Conveniently, manipulation of sequences and production of DNA for transformation may first performed in a bacterial host, e.g. E. coli, and usually vectors will include sequences to facilitate such manipulations, including a bacterial origin of replication and appropriate bacterial selection marker. Selection markers encode proteins necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media. Exemplary vectors and methods for transformation of yeast are described, for example, in Burke, D., Dawson, D., & Steams, T ., Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual, Plainview, NY : Cold Spring Harbor Laboratory Press (2000). Expression vectors for use in the methods of the disclosure may include yeast or mammalian specific sequences, including a selectable auxotrophic or drug marker for identifying transformed host strains. A drug marker may further be used to amplify copy number of the vector in a yeast host cell.

[0246] The polypeptide coding sequence of interest is operably linked to transcriptional and translational regulatory sequences that provide for expression of the polypeptide in the desired host cells, e.g., yeast or mammalian cells. These vector components may include, but are not limited to, one or more of the following: an enhancer element, a promoter, and a transcription termination sequence. Sequences for the secretion of the polypeptide may also be included, e.g. a signal sequence, and the like. An origin of replication, e.g., a yeast or mammalian origin of replication, is optional, as expression vectors may be integrated into the host cell genome.

[0247] Nucleic acids are "operably linked" when placed into a functional relationship with another nucleic acid sequence. For example, DNA for a signal sequence is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites or via a PCR / recombination method familiar to those skilled in the art (GATEWAY®Technology (universalmethod for cloning DNA); Invitrogen, Carlsbad California). If such sites do not exist, the synthetic oligonucleotide adapters or linkers are used in accordance with conventional practice.

[0248] Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequences to which they are operably linked. Such promoters fall into several classes: inducible, constitutive, and repressible promoters (that increase levels of transcription in response to absence of a repressor). Inducible promoters may initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g., the presence or absence of a nutrient or a change in temperature.

[0249] The promoter fragment may also serve as the site for homologous recombination and integration of the expression vector into the same site in the host cell, e.g., yeast or mammalian cell, genome; alternatively, a selectable marker may be used as the site for homologous recombination. Suitable promoters for use in different eukaryotic and prokaryotic cells are well known and commercially available.

[0250] The polypeptides of interest may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, e.g. a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the polypeptide coding sequence that is inserted into the vector. The heterologous signal sequence selected preferably is one that is recognized and processed through one of the standard pathways available within the host cell, e.g., a mammalian cell, an insect cell, or a yeast cell. Additionally, these signal peptide sequences may be engineered to provide for enhanced secretion in expression systems. Secretion signals of interest also include mammalian and yeast signal sequences, which may be heterologous to the protein being secreted, or may be a native sequence for the protein being secreted. Signal sequences include pre peptide sequences, and in some instances may include propeptide sequences. Many such signal sequences are known in the art, including the signal sequences found on immunoglobulin chains, e.g., K28 preprotoxin sequence, PHA-E, FACE, human MCP-1, human serum albumin signal sequences, human Ig heavy chain, human Ig light chain, and the like. For example, see Hashimoto et. ah, Protein Eng., 11(2):75 (1998); and Kobayashi et. ah, Therapeutic Apheresis, 2(4):257 (1998)).

[0251] Transcription may be increased by inserting a transcriptional activator sequence into the vector. These activators are cis-acting elements of DNA, usually about from 10 to 300 bp, which act on a promoter to increase its transcription. Transcriptional enhancers are relatively orientation and position independent, having been found 5' and 3' to the transcription unit, within an intron, as well as within the coding sequence itself. The enhancer may be spliced into the expression vector at a position 5' or 3' to the coding sequence, but is preferably located at a site 5' from the promoter.

[0252] Expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from 3' to the translation termination codon, in untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA.

[0253] Construction of suitable vectors containing one or more of the above-listed components employs standard ligation techniques or PCR / recombination methods. Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the plasmids required or via recombination methods. For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform host cells, and successful transformants selected by antibiotic resistance (e.g. ampicillin or Zeocin) where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and / or sequenced.

[0254] As an alternative to restriction and ligation of fragments, recombination methods based on specific attachment (“ att ”) sites and recombination enzymes may be used to insert DNA sequences into a vector. Such methods are described, for example, by Landy, Ann. Rev. Biochem., 58:913-949 (1989); and are known to those of skill in the art. Such methods utilize intermolecular DNA recombination that is mediated by a mixture of lambda and E. coli -encoded recombination proteins. Recombination occurs between att sites on the interacting DNA molecules. For a description of att sites see Weisberg and Fandy, Site-Specific Recombination in Phage Lambda, in Lambda II, p. 211- 250, Cold Spring Harbor, NY: Cold Spring Harbor Press (1983). The DNA segments flanking the recombination sites are switched, such that after recombination, the att sites are hybrid sequences comprised of sequences donated by each parental vector. The recombination can occur between DNAs of any topology.

[0255] Att sites may be introduced into a sequence of interest by ligating the sequence of interest into an appropriate vector; generating a PCR product containing att B sites through the use of specific primers; generating a cDNA library cloned into an appropriate vector containing att sites; and the like.

[0256] Folding, as used herein, refers to the three-dimensional structure of polypeptides and proteins, where interactions between amino acid residues act to stabilize the structure. While non-covalent interactions are important in determining structure, usually the proteins of interest will have intra- and / or intermolecular covalent disulfide bonds formed by two cysteine residues. For naturally occurring proteins and polypeptides or derivatives and variants thereof, the proper folding is typically the arrangement that results in optimal biological activity, and can conveniently be monitored by assays for activity, e.g. ligand binding, enzymatic activity, etc.

[0257] In some instances, for example where the desired product is of synthetic origin, assays based on biological activity will be less meaningful. The proper folding of such molecules may be determined on the basis of physical properties, energetic considerations, modeling studies, etc.

[0258] The expression host may be further modified by the introduction of sequences encoding one or more enzymes that enhance folding and disulfide bond formation, i.e. foldases, chaperonins, etc. Such sequences may be constitutively or inducibly expressed in the host cell, using vectors, markers, etc. as known in the art. Preferably the sequences, including transcriptional regulatory elements sufficient for the desired pattern of expression, are stably integrated in the yeast genome through a targeted methodology.

[0259] For example, the eukaryotic protein disulfide isomerase (“PDF’) is not only an efficient catalyst of protein cysteine oxidation and disulfide bond isomerization, but also exhibits chaperone activity. Co-expression of PDI can facilitate the production of active proteins having multiple disulfide bonds. Also of interest is the expression of immunoglobulin heavy chain binding protein ( BIP ): cyclophilin; and the like.

[0260] Cultured mammalian cells are exemplary hosts for production of the disclosed anti-CoV-S antibodies and antigen-binding fragments thereof. As mentioned CHO cells are particularly suitable for expression of antibodies. Many procedures are known in the art for manufacturing monoclonal antibodies in mammalian cells. (See, Galfre, G. and Milstein, C ., Methods Enzym., 73:3-46, 1981; Basalp et al, Turk. J. Biol., 24:189-196, 2000; Wurm, F.M., Nat. Biotechnol, 22:1393-1398, 2004; and Li et al, mAbs, 2(5):466-477, 2010). As mentioned in further detail infra, common host cell lines employed in mammalian monoclonal antibody manufacturing schemes include, but are not limited to, human embryonic retinoblast cell line PER.C6® (Crucell N.V., Leiden, The Netherlands), NS0 murine myeloma cells (Medical Research Council, London, UK), CV1 monkey kidney cell line, 293 human embryonic kidney cell line, BHK baby hamster kidney cell line, VERO African green monkey kidney cell line, human cervical carcinoma cell line HELA, MDCK canine kidney cells, BRL buffalo rat liver cells, W138 human lung cells, HepG2 human liver cells, MMT mouse mammary tumor cells, TRI cells, MRC5 cells, Fs4 cells, myeloma or lymphoma cells, or Chinese Hamster ( Cricetulus griseus) Ovary (CHO) cells, and the like. Many different subclones or sub-cell lines of CHO cells known in the art that are useful and optimized for production of recombinant monoclonal antibodies, such as the DP 12 (CHO K1 dhfr-) cell line, NS0 cells are a non-Ig secreting, non-light chain- synthesizing subclone ofNS-1 cells that are resistant to azaguanine. Other Chinese Hamster and CHO cells are commercially available (from ATCC, etc.), including CHO-DXB11 (CHO-DUKX), CHO- pro3, CHO-DG44, CHO 1-15, CHO DP-12, Lec2, M1WT3, Lec8, pgsA-745, and the like, all of which are genetically altered to optimize the cell line for various parameters. Monoclonal antibodies are commonly manufactured using a batch fed method whereby the monoclonal antibody chains are expressed in a mammalian cell line and secreted into the tissue culture medium in a bioreactor. Medium (or feed) is continuously supplied to the bioreactor to maximize recombinant protein expression. Recombinant monoclonal antibody is then purified from the collected media. In some circumstances, additional steps are needed to reassemble the antibodies through reduction of disulfidebonds, etc. Such production methods can be scaled to be as large as 10,000 L in a single batch or more. It is now routine to obtain as much as 20 pg / cell / day through the use of such cell lines and methodologies, providing titers as high as 10 g / L or more, amounting to 15 to 100 kg from bioreactors of 10 kL to 25 kL. (Li etal, 2010). Various details of this production methodology, including cloning of the polynucleotides encoding the antibodies into expression vectors, transfecting cells with these expression vectors, selecting for transfected cells, and expressing and purifying the recombinant monoclonal antibodies from these cells are provided below.

[0261] For recombinant production of an anti-CoV-S antibody or antigen-binding fragment in mammalian cells, nucleic acids encoding the antibody or fragment thereof are generally inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. DNA encoding the antibody is readily isolated or synthesized using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to DNAs encoding the heavy and light chains of the antibody). The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Selection of promoters, terminators, selectable markers, vectors, and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are known in the art and are available through commercial suppliers.

[0262] The antibodies of this disclosure may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.The homologous or heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available.

[0263] Such expression vectors and cloning vectors will generally contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Typically, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses, e.g., the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2mu plasmid origin is suitable for yeast, and various viral origins (Simian Virus 40 (“SV40”), polyoma, adenovirus, vesicular stomatitis virus (“VSV”), or bovine papillomavirus (“BPV”) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

[0264] These vectors will also typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.

[0265] One example of a se...

Claims

ClaimsWhat is claimed is:

1. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a sequence having at least 90% identity to SEQ ID NO:22302 and a light chain variable region (VL) comprising a sequence having at least 90% identity to SEQ ID NO: 22312.

2. The isolated antibody, or antigen-binding fragment thereof, of claim 1, comprising a VH comprising a sequence having at least 95% identity to SEQ ID NO:22302 and a VL comprising a sequence having at least 95% identity to SEQ ID NO:22312.

3. The isolated antibody, or antigen-binding fragment thereof, of claim 1 or claim 2, wherein the VH comprises a VH complementarity determining region 1 (CDR1) comprisingSEQ ID NO:22304, a VH complementarity determining region 2 (CDR2) comprising SEQ ID NO:22306, and a VH complementarity determining region 3 (CDR3) comprising SEQ ID NO:22308, and wherein the VL comprises a VL CDR1 comprising SEQ ID NO:22314, a VL CDR2 comprising SEQ ID NO:22316, and a VL CDR3 comprising SEQ ID NO:22318.

4. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR1 comprising SEQ ID NO:22304, a VH CDR2 comprising SEQ ID NO:22306, and a VH CDR3 comprising SEQ ID NO:22308, and a light chain variable region (VL) comprising a VL CDR1 comprising SEQ ID NO:22314, a VL CDR2 comprising SEQ ID NO:22316, and a VL CDR3 comprising SEQ ID NO:22318.

5. The isolated antibody, or antigen-binding fragment thereof, of claim 4, wherein the VH comprises a sequence having at least at least 90% identity to SEQ ID NO:22302 and VL comprising a sequence having at least 90% identity to SEQ ID NO:22312.

6. The isolated antibody, or antigen-binding fragment thereof, of claim 4 or claim 5, wherein the VH comprises a sequence having at least at least 95% identity to SEQ ID NO:22302 and VL comprising a sequence having at least 95% identity to SEQ ID NO:22312.

7. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, wherein the VH comprises SEQ ID NO:22302 and the VL comprises SEQ ID NO:22312.

8. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of ARDFSGHTAXiAGTGFEY (SEQ ID NO: 23209), wherein Xi is W or V; a VH CDR2 having a sequence of SISX1DGYX2TYYPDSLKG (SEQ ID NO: 23208), wherein Xi is S or E and X2 is N or S; and a VH CDR1 having a sequence of X1TFX2SYYX3X4 (SEQ ID NO: 23206), wherein Xi is F or Y, X2 is T or S, X3 is M or I, and X4 is H or N; and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QSYDSSLSVLYXi (SEQ ID NO: 23214), wherein Xi is T or V; a VL CDR2 having a sequence of GX1SSX2X3S (SEQ ID NO: 23212), wherein Xi is S or A, X2 is R or L, and X3 is N, H, or Q; and a VL CDR1 having a sequence of TSGX1SNX2GAGYX3VH (SEQ ID NO: 23210), wherein Xi is N or S, X2 is I or V, and X3 is D or Y.

9. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR3 having a sequence of VKDGGYYD S SGPGH (SEQ ID NO: 23218); a VH CDR2 having a sequence of AINLNGDSXiYYTDSVRG (SEQ ID NO: 23217), wherein Xi is K or T; and a VH CDR1 having a sequence of FTFS X1X2AMH (SEQ ID NO: 23215), wherein Xi is Ror K and X2 is F or Y; and a light chain variable region (VL) comprising a VL CDR3 having a sequence of QQRXiNWPQN (SEQ ID NO: 23225), wherein Xi is A or S; a VL CDR2 having a sequence of DXiS X2RAT (SEQ ID NO: 23223), wherein Xi is A, S, or V, X2 is K or R; and a VL CDR1 having a sequence of RASENIXiHYLA (SEQ ID NO: 23220), wherein Xi is L or A.

10. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein the antibody, or antigen-binding fragment thereof,comprises a heavy chain variable region (VH) comprising a VH CDR1 of an antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, a VH CDR2 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a VH CDR3 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a light chain variable region (VL) comprising a VL CDR1 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, a VL CDR2 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a VL CDR3 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36.

11. The isolated antibody, or antigen-binding fragment thereof, of claim 10, wherein the VH comprises a sequence having at least at least 90% identity to the VL sequence of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36 and VL sequence having at least 90% identity to the VL sequence of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36.

12. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a sequence having at least 90% identity to a VH protein sequence of an antibody selected from the group consisting of the antibodies listed in Fig. 1 and Fig. 36, and a light chain variable region (VL) comprising a sequence having at least 90% identity to a VL protein sequence of the antibody listed in Fig. 2.

13. The isolated antibody, or antigen-binding fragment thereof, of claim 12, wherein the heavy chain variable region (VH) comprises a VH CDR1 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, a VH CDR2 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a VH CDR3 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a light chain variable region (VL) comprising a VL CDR1 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig.2, or Fig.36, a VL CDR2 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36, and a VL CDR3 of the antibody selected from the group consisting of the antibodies listed in Fig. 1, Fig. 2, or Fig. 36.

14. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, wherein the COV-S is the spike protein of SARS-CoV (“SARS-CoV-S”) or the spike protein of SARS-CoV-2 (“SARS-CoV-2-S”).

15. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, wherein the antibody, or antigen-binding fragment thereof, cross-reacts with SARS-CoV-S and SARS-CoV-2-S.

16. The isolated antibody, or antigen-binding fragment thereof, of claim 14 or claim 15 , wherein SARS-CoV-S comprises a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1, and wherein SARS-CoV-2-S comprises a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 5.

17. The isolated antibody, or antigen-binding fragment thereof, of any one of claims 14-16, wherein the SARS-CoV-2-S is a B.1.1.7 variant, a B. 1.351 variant, a B.1.1.28 variant, a B. 1.429 variant, a B. 1.427 variant, or a B.1.525 variant.

18. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, which neutralizes SARS-CoV and / or SARS-CoV-2.

19. The isolated antibody, or antigen-binding fragment thereof, of claim 18, which neutralizes SARS-CoV and / or SARS-CoV-2 with an IC50 of about 100 nM or lower.

20. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, which binds to CoV-S with a KD value of about 100 nM or lower.

21. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, wherein the antibody is human, humanized, primatized, chimeric, bispecific or multispecific.

22. The isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims, wherein the antigen-binding fragment thereof comprises a Fab, Fab2, or scFv.

23. An isolated antibody, or antigen-binding fragment thereof, which competes for binding with the isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims.

24. An isolated antibody, or antigen-binding fragment thereof, which binds the same epitope as the isolated antibody, or antigen-binding fragment thereof, of any one of the previous claims.

25. An antibody drug conjugate (“ADC”) comprising the antibody, or antigen-binding fragment thereof, of any one of the previous claims, and a drug.

26. A chimeric antigen receptor (“CAR”) comprising at least one antibody, or antigen-binding portion thereof, of any one of claims 1-24.

27. An isolated nucleic acid encoding the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, or the CAR of claim 26.

28. An isolated cell comprising the isolated nucleic acid of claim 27, or expressing the isolated antibody or antigen-binding fragment thereof, of any one of claims 1-24, or the CAR of claim 26.

29. A composition comprising the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, the ADC of claim 25, or the CAR of claim 26.

30. A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of any one of claims 1 -24, the ADC of claim 25 , or the CAR of claim 26, and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, further comprising a second antibody, or antigen-binding fragment thereof, wherein the second antibody, or antigen-binding fragment thereof, is selected from the group consisting of ADI-58122, ADI-58127, ADI-58129 or ADI-58131.

32. A kit comprising the antibody of any one of claims 1-24, the ADC of claim 25, the CAR of claim 26, the composition of claim 29, or the pharmaceutical composition of claim 30 or claim 31, and instructions for use.

33. A method of producing the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, or the CAR of claim 26, the method comprising (a) culturing a cell expressing the antibody, or antigen-binding fragment thereof, or the CAR under conditions that permit expression and (b) isolating the antibody, or antigen-binding fragment thereof, or the CAR from the cell, or the culture medium comprising the cell.

34. A method of determining whether a subject has been infected with SARS-CoV or SARS- CoV-2, the method comprising detecting whether a biological sample from said subject comprisesSARS-CoV-S protein or SARS-CoV-2-S protein based on an immunoreaction with at least one of the antibodies, or antigen-binding fragments thereof, of any one of claims 1-24.

35. A method of inducing an immune response against SARS-CoV, SARS-CoV-2, or another coronavirus selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV- 229E, and HCoV-NL63 in a subject in need thereof, the method comprising administering at least one antibody, or antigen-binding fragment thereof, of any one of claims 1-24, at least one ADC of claim 25, or at least one CAR of claim 26, or the pharmaceutical composition of claim 30 or claim 31.

36. A method of preventing infection of susceptible cells by SARS-CoV, SARS-CoV-2, or another coronavirus selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 in a subject in need thereof, the method comprising administering the antibody, or antigen-binding fragment thereof, of any one of claims 1-22, at least one ADC of claim 23, or at least one CAR of claim 26, or the pharmaceutical composition of claim 30 or claim 31.

37. A method of treating a coronavirus infection of a subject by SARS-CoV, SARS-CoV-2, or another coronavirus selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 in a subject in need thereof, the method comprising administering the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, at least one ADC of claim 25, or at least one CAR of claim 26, or the pharmaceutical composition of claim 30 or claim 31.

38. A method of treating a symptom of an infection of a subject by SARS-CoV, SARS-CoV-2, or another coronavirus selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63 in a subject in need thereof, the method comprising administering the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, at least one ADC of claim 25, or at least one CAR of claim 26, or the pharmaceutical composition of claim 30 or claim 31.

39. The method of claim 38, wherein the symptom comprises at least one of bronchitis, pneumonia, respiratory failure, acute respiratory failure, organ failure, multi-organ system failure, pediatric inflammatory multisystem syndrome, acute respiratory distress syndrome, blood clot, a cardiac condition, myocardial injury, myocarditis, heart failure, cardiac arrest, acute myocardial infarction, dysrhythmia, venous thromboembolism, post-intensive care syndrome, shock, anaphylactic shock, cytokine release syndrome, septic shock, disseminated intravascular coagulation, ischemic stroke, intracerebral hemorrhage, microangiopathic thrombosis, psychosis, seizure, nonconvulsive status epilepticus, traumatic brain injury, stroke, anoxic brain injury, encephalitis, posterior reversible leukoencephalopathy, necrotizing encephalopathy, post-infectious encephalitis, autoimmune mediatedencephalitis, acute disseminated encephalomyelitis, acute kidney injury, acute liver injury, pancreatic injury, immune thrombocytopenia, subacute thyroiditis, a gastrointestinal complication, aspergillosis, increased susceptibility to infection with another virus or bacteria, and / or a pregnancy-related complication.

40. A method of decreasing the risk of mortality, hospitalization, mechanical ventilation, or a combination thereof, in a subject infected by SARS-CoV, SARS-CoV-2, or another coronavirus selected from the group consisting of MERS-CoV, HCoV-HKUl, HCoV-OC43, HCoV-229E, and HCoV-NL63, the method comprising administering to the subject a therapeutically effective amount of the antibody, or antigen-binding fragment thereof, of any one of claims 1-24, the ADC of claim 25, or the CAR of claim 26.

41. The method of any one of claims 34-40, wherein the subject is a human subject.

42. The method of any one of claims 34-41, wherein the subject has at least one risk factor which renders them more prone to a poor clinical outcome.

43. The method of claim 42, wherein the at least one risk factor is selected from the group consisting of: an old age selected from the group consisting of over 55, over 60 or over 65 years old; diabetes, a chronic respiratory condition, obesity, hypertension, a cardiac or cardiovascular condition, a chronic inflammatory or autoimmune condition, and an immune compromised status.

44. The method of any one of claims 34-43, wherein the antibody, or the antigen-binding fragment thereof, is administered intramuscularly or intravenously.

45. The method of any one of claims 34-44, wherein the antibody, or the antigen-binding fragment thereof, is administered at a dose of about 100 mg to about 2000 mg, about 200 mg to about 1500 mg, about 300 mg to about 600 mg, about 500 mg to about 1200 mg, or about 300 mg to about 1200 mg.

46. The method of any one of claims 34-45, wherein the antibody, or antigen-binding fragment thereof, is administered once or is administered weekly.